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This thesis describes the synthesis of a family of amino acids containing a ketone 
functionalised side-chain (I, II, III), which are analogues of one of the amino acids 
found in the cyclic tetrapeptide apicidin (IV).  Cross metathesis of the alkenes (V, VI, 
VII) with a range of unsaturated ketones, followed by hydrogenation, gave the tar-
get amino acids in excellent yields.  The required alkenes were prepared in moder-
ate to good yield by the copper-catalysed allylation of the homologous organozinc 





























Scheme for overall synthesis from zinc reagent to ketone 
 
In initial cross-metathesis experiments using the alkene (V), a highly diastereoselec-
tive cyclisation to give the trans-pyrrolidines (XIb) was observed.  After careful 
study, it was established that the cyclisation occurred on standing in CDCl3, and that 
it could also be achieved in a more controlled way by using catalytic amounts of dry 










The alkene (VI) was incorporated into the linear tetrapeptide (XII), which was then 
cyclised to give the cyclic tetrapeptide (XIII) along with the cyclic octapeptide (XIV).  
Cross metathesis of the cyclic tetrapeptide (XIII) with methyl vinyl ketone and pro-
pyl vinyl ketone, followed in each case by hydrogenation, gave the two modified 
cyclic peptides (XV) and (XVI) in good yield, demonstrating the feasibility of the 
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Chapter 1: Introduction  
1.1 Background 
Deoxyribonucleic acid (DNA) is a fundamental part of living organisms. Its function is 
the long term storage of genetic information. It is used in both transcription and 
translation to produce proteins and its structure is tightly bound in active chromo-
somes.1-3 Transcription makes a copy of a single chain of double stranded helical 
DNA, or a section of it. In order to get transcription it is necessary to open the DNA 
double helix (Figure 1 fibre) so that the RNA polymerase can bind to a section of the 
DNA template (Figure 1 beads on a string structure). Remodeling of histone protein 
that package chromosomal DNA by acetylation is one method that can be used to 
change from fibre to beads on a string packing.1,4-6  
 
 
                                  






Figure 1. Different stages of chromatin packing to give condensed chromosome
7
 
 Histone acetyltransferase (HAT) and histone deacetylase (HDAC) are enzymes that 
regulate the acetylation state of the histone core. HDAC has been found in bacteria, 
fungi, plants and animals and catalyses the deacetylation of N-acetylated lysine res-
idues in histone proteins. The positively charged N-terminal tails of the lysine resi-
dues in the histones bind to negatively charged DNA. An increase in this interaction 
leads to cell division, and is controlled by lysine modification. Neutralization of the 
positive charge by HAT leads to decreased interactions between the histone and 
DNA, and it allows transcription factor to separate the DNA chain where the gene is 
 
2 
to be transcribed to make mRNA. Therefore, the acetylation of histones plays a vital 
role in the transcriptional response of the cell. A lack of balance between acetyla-
tion and deacetylation leads to abnormal behavior of the cells in morphology, cell 
cycle, differentiation, and carcinogenesis. For these reason HDAC has been consid-












Inhibition of HDAC leads to a reduction in the concentration of the fibre structure 
(Figure 2) compared with the beads on a string structure (Figure 2). As a result RNA 
polymerase is free to bind and perform transcription because Zn2+ in the active site 
pocket of HDAC, binds to oxygen of N-acetylated histone lysine residues.              
Subsequent hydrolysis of the amide produces positively charged N-terminal tails.6,7 
Cyclic tetrapeptides are natural products that have been shown to inhibit the activi-
ty of HDAC. This class of macrocyclic peptide consists of a large hydrophobic cap 
group with a long side-chain formed by incorporation of 2-amino-8-oxo-decanoic 
acid (Aoda), 2 or an analogue such as Aoe, 3.16-20 Apicidin 1, a natural product iso-
lated from endophytic fungi on twigs (Fusarium sp.) collected in Costa Rica21,22 (Fig-
ure 3) is an example. Apicidin is structurally related to a family of α-epoxyketone 
cyclic tetrapeptides      (4-8) which are known histone deacetylase inhibitors (HDACi) 































1.2 Biological activity 
Bioactive cyclic peptides are synthetic targets for medicinal chemists. In general, 
due to enzymatic degradation linear peptides are not as stable as their cyclic 
equivalents in vivo. Stability is a crucial requirement for drug candidates in vivo, 
therefore the preparation small cyclic peptides is of great importance to medicinal 
chemists.34,35 HDACi act to mimic access of HDAC to acetylated lysine residues. A 
suggested mechanism for this process is the binding of a zinc ion in the active site 
pocket of HDAC to the functional group in the side chain of the cyclic tetrapeptide. 
In the case of Aoda and Aoe, zinc binds to the ketone in the 8-position and in tri-









Apicidin 1 induces both mammalian and parasite histone hyperacetylation. It has 
been shown to have broad biological action towards the apicomplexan family of 
protozoan parasites and prevents the growth of intracellular parasites that lead to 
diseases such as malaria and coccidisis.21,36 Trapoxin A, 4 isolated from the fungus 
Helicoma ambiens, has been found to strongly affect mammalian cell growth and 
morphology33 (Figure 4 ). Several groups have shown that removing the epoxide 
group by reduction or hydrolysis removes biological activity, suggesting trapoxin 
may bind irreversibly to its target.29,33,37,38 Horinouchi and co-workers synthesized a 
novel, potent, analogue of trapoxin containing a hydroxamic acid instead of the 
Figure 5. Proposed coordination to zinc in cyclic tetrapeptides and chelating in TSA, 9 
 
5 
epoxyketone as the only modification. At low nanomolar concentration the hybrid 
compound was shown to act as a reversible HDAC inhibitor.39 In contrast, when ana-
logues of chlamydocin containing hydroxamic acid compounds 11, 12 were tested 
they showed less potent HDAC inhibitory activity than reference compound 10 (Fig-
ure 6). The different inhibitory effects on HDAC of compounds  10-12 may be due to 
the presence of a cyclic amino acid residue in 10, because it affects the orientation 













The varying cytotoxicity of cyclic tetrapeptide inhibitors can be attributed to a  
number of factors, including the conformation of the peptide backbone in solution, 
the overall polarity of the peptide, which in turn affects the ability of inhibitors to 
cross cellular and nuclear membranes, and the functionality of the amino acid      
residues which can coordinate to Zn2+.9 
Due to the limited supply of these biologically important compounds found in      
nature, they have attracted the interest of researchers. Therefore, the synthesis of 
several HDAC inhibitors with different chemical structures has been extensively 
studied.  
Figure 6. Chlamydocin containing hydroxamic acid 
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1.3 Different routes to synthesis 2-amino-8-oxo-decanoic acid 2 
A number of routes towards Aoda have been reported. The first approach was     
reported in 1985 by Viallefont and co‐workers41 and involved reaction of the iodide 
13, derived from protected aspartic acid, with an organocuprate 14. Subsequent 










In 2001, Singh and Mou42 reported the preparation of ketone 16 by the                   
photochemically induced reaction of the iodide 18 with the unsaturated ketone 17 











Scheme 1. Synthesis of Aoda 
Scheme 2. Synthesis of Aoda by radical generation 
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In 2004 new methodology reported by Moody and co-workers43 used a highly          
diastereoselective addition reaction between oxime 19 and vinyllithium 20 to give    
adduct 21. The N-O bond was cleaved, followed by N-protection to give 22.          




























Scheme 3. New methodology: Asymmetric synthesis of Aoda 
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In 2006 Taddei and co-workers16 used a different approach to elongate an                
enantiomerically pure amino acid, using a Wadsworth Emmons reaction between 
aldehyde 29 and phosphonate 30 (Scheme 4). Compound 29 was synthesized from 
S-glutamic acid 24 (Scheme 4), by double protection of the amine and -COOH using 
benzyl bromide, followed by selective reduction of the benzyl ester to give the cor-
responding alcohol 26 and oxidation under Swern conditions. Finally, homologation 
with methoxymethyl triphenylphosphonium chloride and LiHMDS, followed by acid-
ic work up, gave the aldehyde, 29. Aoda was then obtained through hydrogenation 






















 Scheme 4. Synthesis of Aoda by Wadsworth Emmons reaction from aldehyde 29 
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In the same year Alajarin and co-workers44 prepared Aoda using the Wittig reaction, 
by treatment of phosphonium salt 33 with LiHMDS, followed by addition of alde-
hyde 32 derived from glutamic acid (Scheme 5). The salt 33 was prepared from 1-
chloropentan-3-one. The alkene 34, obtained as a mixture of isomers was converted 





















Scheme 5. Synthesis of Aoda by Wittig reaction 
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1.4  Previous total syntheses of natural macrocyclic tetrapeptides  
1.4.1 Synthesis of chlamydocin 
In 1993, Godfrey and co-workers45 reported a synthesis of chlamydocin 5. They 
chose to form the cyclic tetrapeptide by cyclization between the N-terminus of 
(Aoe) and the active ester of proline in the linear tetrapeptide precursor 37. They          
preferred to use (S)-2-amino-5-chloropentanoic acid (ACP) rather than                          
(S)-2-amino-5-iodopentanoic acid (AIP) as a residue in compound 37 because there 
is a greater chance of intramolecular nucleophilic displacement of the iodide group 
by reaction with the primary amino group to give 38 46 (Scheme 6). In addition, the 
iodo group is not compatible with hydrogenolysis conditions. Chlorination of       
protected hydroxyamino acid 39 gave diprotected chloroamino acid 40, which was 
deprotected using TFA to give N-Z-(S)-2-amino-5-chloropentanoic acid 41. 47,48 Cou-
pling of (S) phenylalanine t-butyl ester 42 with Z-α-aminoisobutyric acid 43 followed 
by ester deprotection gave dipeptide 44, which was coupled with (R)-proline to give 
tripeptide 46. Hydrogenolysis of 46 to give 47 followed by coupling with 41, using 
BOP 49 produced the desired tetrapeptide 48, which was  saponified then reacted 
with pentafluorophenol. Chlorocyclopeptide 50 was converted to iodo cyclopeptide 
under a Finkelstein exchange and subsequent radical reaction and desilylation gave 









































Scheme 7. Synthesis of chlamydocin, 5 by Godfrey and co-workers 
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1.4.2 Synthesis of trapoxin 
In 1996 Schreiber and co-workers33 reported a synthesis of trapoxin 4. In this         
synthesis, cyclization was achieved between the N-terminus residue of                   
(2S, 9S)-2-amino-8-oxo-9, 10-epoxydecanoic acid (Aoe) and the C-terminus residue 
of (R)–proline. Hydrogenation and debenzylation of olefin 52 followed by 
bromination of the alcohol group gave 53. Transmetalation of the Grignard reagent 
derived from 53 with CuBr.DMS followed by reaction with Z-serine β-lactone 54 
gave acid 55, which was coupled with tripeptide 56. Finally the cyclization of 57 was 
achieved using BOP and DMAP in DMF. Removal of the TIPS protecting group with 
TBAF gave 51% yield of the pure cyclotetrapeptide alcohol 58 over two steps 




















  Scheme 8. Synthesis of trapoxin 4 by Schreiber and co-workers 
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The cyclic peptide 58 was converted into trapoxin by formation of the primary      
tosylate, treatment with aqueous HCl to remove the acetonide and then 
DBU/MeOH to give epoxide in 62% yield. Finally Moffatt oxidation gave the target 
compound 4, 80% (Scheme 8).The same method was used in a total synthesis of 
chlamydocin; the main difference was the presence of an aminoisobutyric acid (Aib) 
residue adjacent to the (Aoe) residue rather than phenylalanine as in trapoxin.33 
1.5 Synthesis of analogues of apicidin 
In 2001 Singh and Mou42 synthesized desmethoxy apicidin 68 starting from               
Z-L-glutamic acid 59. Cyclization in the presence of formaldehyde, followed by reac-
tion of 60 with methoxide gave 90% of monomethyl ester 61. Reduction of 61 via 
the anhydride gave alcohol 62 which was further transformed to iodide 18 in 83% 
yield. The final reaction in this route is the radical addition of ethyl vinyl ketone 17 
to 18 under conditions already shown in scheme 2 to make Aoda. For the synthesis 
of the cyclic tetrapeptide, cyclisation at the R-pip amide bond was chosen because 
recent report51 screened cyclisation of other peptides incorporating R-pro with high 
yield. All coupling reactions were carried out using DCC/HOBt. After saponification 
and removal of the (Z) group, all attempts to cyclize failed, which the researchers        
ascribed to the present of the indole nitrogen. Therefore the indole was protected 
using a Boc group in 93% yield, followed by saponification of the methyl ester group 
of the pipecolic residue in compound 64. The corresponding pentafluorophenyl es-
ter 66 was formed from the linear tetrapeptide 65 using pentafluorophenol, 1-(3-
dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride (EDAC) and a catalytic 
amount of DMAP and, finally, cyclization was achieved using the modified Schmidt    

































 Scheme 9. Synthesis of analogues of apicidin 
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1.6 Chemistry of apicidin 
1.6.1 Side chain reactions of Aoda 2 
In 2000, Meinke and co-workers53 reported that α-hydroxylation of the side chain 
ketone of natural apicidin 1 gave a mixture (1 : 1) of compounds 69 and 70, which 
could be separated. The mixture was subjected to oxidative cleavage leading to the 


















Scheme 10. Oxidative cleavage of side chain of apicidin 
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1.6.2 Tryptophan replacement in N-desmethoxy apicidin 
In 2000 Colletti and co-workers36 reported oxidation of the β-position of tryptophan 
in compound 68, the analogue of apicidin whose synthesis was described in scheme 
9, to furnish β-oxo derivative 73. Using Et3N in CH2Cl2 or t-BuOK, t-BuOH-THF, 73 
was quantitatively epimerized to give compound 74. Oxidation of the indole in 
compound 68 using ruthenium tetraoxide 54-56 gave the methyl aspartate derivative 
75 in good yield. Similar conditions were used with compound 73 to give methyl es-
ter 76 (Scheme 11). Reduction of side chain C8 ketones of 75 and 76 gave their re-
spective C8 alcohols and the methyl esters were then transformed to the corre-
sponding N-methoxy-N-methyl amide 77 and 78. This reduction was carried out to 
protect the ketone during subsequent organometallic addition. On treatment of 
Weinreb amides 77 and 78 with Grignard reagents or aryl lithiums, ketones 79, 80 




































Scheme 11. Ketone analogues of apicidin 
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Bromination of the tryptophan unit was achieved using either pyridinium bromide 
perbromide, or NBS, to furnish the 2-bromoindole derivative 81 which was subse-
quently subjected to coupling with various aryl boronic acids under Suzuki condi-











1.6.3 Further reactions of apicidin 
In 2002 Singh and co-workers57 reported that reduction of apicidin by NaBH4 gave a    
( 1 : 1 ) mixture of the inseparable diastereoisomeric alcohols 83 as shown in 







Scheme 12. 2-Arylindole analogs of apicidin and different aryl group on position 2 of indole 
Scheme 13. Reduction of side chain of apicidin 1 
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Reaction of compound 83 with Ac2O gave the acetates 84. Mesylation of alcohol 83 
by reaction with methanesulfonyl chloride followed by elimination with DBU gave a 





















Scheme 14. Side chain modification of 83 
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Treatment of apicidin 1 with acidic ethanol gave the linear tetrapeptide 87 formed 
by selective cleavage of the amide bond between Pip and lle. Hydrolysis of the ethyl 
ester 87 with LiOH furnished the acid 88 (Figure 7), but attempted recyclization us-
ing BOP reagent in DMF failed. This was ascribed to the steric effect of IIe because 
cyclization has been successfully achieved between Pro-NH and Phe-CO2H in ana-

















Figure 7. Selective cleavage of the amide bond between Pip and lle 
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1.7 Olefin-Cross metathesis 
Olefin cross metathesis (CM) is a potentially powerful synthetic method; however 
CM has been limited by the lack of predictability in product selectivity and stereose-
lectivity (Scheme 15). However by placing sterically large and electron-withdrawing 
groups near the reacting olefin there is the possibility to improve cross-metathesis 






The first report using the first generation Grubbs catalyst in cross-metathesis ap-
peared at the end of 1996.65 Later Grubbs introduced N-heterocyclic carbenes 
(NHCs) Lewis basic ligands, in place of one phosphonium ligand in 89 producing the 
2nd generation catalyst 90. Subsequently, modified catalysts were developed includ-
ing the Hoveyda Grubbs 1st generation catalyst 91 with an ortho-isoproxy group and 








Figure 8. Metathesis catalysts 
Scheme 15. Cross metathesis product 
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The Grubbs 2nd generation catalyst has improved stability and activity in cross-
metathesis and ring-closing metathesis (RCM) reactions. Macrocycle 94 was ob-
tained successfully from ring closing metathesis reaction followed by hydrogenation 
to give 95 (Scheme 16). Compound 95 shows less biological activity as HDACi in 
HeLa cell compared to natural apicidin, which may be due to the fact that its core 


















Scheme 16. Synthesis of apicidin analogues by RCM 
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1.7.1 Cross-metathesis reactions of unsaturated amino acids 
In 1998 Gibson and co-workers70 reported the cross-metathesis of homoallyl glycine 
derivatives with aryl- and alkyl-substituted alkenes. The amine and acid groups were 
protected to make sure that amino acid functionality did not interfere. Typical 
yields of the cross-metathesis products using styrene were around 50% with the 
mass balance being the self-metathesis products 102-104 (Scheme 17).                  
For cross-metathesis the trans isomer predominated. As can be seen from the      
results (Table 1) the N-protecting group has little influence on the yield of desired 

















Entry ST R1 Desired Isolated yield % Dimer Isolated yield % 
1 96 Boc 99 52 102 40 
2 97 Phth 100 55 103 35 
3 98 Ac 101 43 104 48 
Scheme 17. Metathesis reaction by using Grubbs 1
st
 generation catalyst 
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When the reaction was extended to 1-octene (Scheme 18), it is clear that by         
decreasing the number of carbon atoms in the amino acid chain, the yield of the 
product decreased (Table 2). The authors suggest that the most likely explanation is 
that the sterically bulky amino acid moiety is hindering the approach of the catalytic 



















Entry ST n Desired Isolated yield % Dimer Isolated yield % 
1 96 2 107 66 102 28 
2 105 1 108 45 110 17 
3 106 0 109 7 111 --- 
Scheme 18. Metathesis reaction using Grubbs 1
st
 generation catalyst 
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In 2005 Kennan and co-workers71 reported the synthesis of analogues of glutamic 







Also in 2005 Blechert and co-workers72 reported a cross-metathesis reaction         
between protected racemic allyl glycine 116 and methyl vinyl ketone 117 using the 
phosphine free ruthenium catalyst (Hoveyda Grubbs 2nd generation catalyst) to give 












Scheme 19. Metathesis reaction using Grubbs 2
nd
 generation catalyst 
Scheme 20. Metathesis reaction using Hoveyda Grubbs 2
nd
 generation catalyst 
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In 2013 Carter and co-worker73  generated compound 121 in good yield by reaction 
of 119 and crotonaldehyde 120, using Hoveyda-Grubbs 2nd generation catalyst and 
the product was shown to be stable in frozen benzene for an extended period 






In 2013 Joseph and co-workers74 prepared the symmetrical double Michael accep-
tor 124  by double cross-metathesis of 1,5-hexadiene 122 with Weinreb acrylamide 











Scheme 21. Synthesis of enal 
Scheme 22. Two directional CM of compound 122 
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1.8 Jackson group chemistry  
The zinc reagent 125 was converted into the corresponding zinc/copper reagent, 
using stoichiometric CuCN.2LiCl, and then treated with methyl vinyl ketone in the 
present of TMSCl to give the adduct 126 75 ( Scheme 23). Later, it was shown that 
catalytic amounts of copper bromide dimethyl sulfide could replace the stoichio-
metric amounts of copper cyanide. Copper catalyzed reaction of methyl and ethyl 
vinyl ketone with the serine and glutamic acid derived zinc reagents 127 and 129, 
gave respectively, analogues of Aoda 128, 130 unfortunately the yield of protected 
















Scheme 23. Synthesis of Aoda and its analogues through Michael addition 
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1.9 Aims of the project 
Cyclic peptides, specifically cyclic tetrapeptides, have a range of useful biological 
properties. We therefore propose to develop new synthetic approach to analogues 
of apicidin 1 a known histone deacetylase inhibitor, which shows in vivo activity 
against plasmodium berhei malaria in mice at low doses and is also known to inhibit 
proliferation of tumour cells.78,79 The octan-6-one side-chain is structurally related 
to the side chains found in a series of other naturally occurring cyclic tetrapeptides, 
including HC-toxin, Trapoxin A, WF- 3161, Cly-2, and chlamydocin 5. The significant 
difference is that in all these compounds, the functional group is a terminus epoxy 
ketone; illustrated by the structure of chlamydocin 5 (Figure 9). It is the 








Our route to cyclic tetrapeptides can follow one of two strategies, synthesis of the 
required amino acid analogues of Aoda or late stage modification of a tetrapeptide 
to produce the desired structure.  
In the first strategy, Aoda and its analogues can in principle be made by reaction of 
organozinc reagents derived from serine, aspartic acid and glutamic acid with allyl 
chloride, followed by cross-metathesis with different unsaturated ketones using 
Grubbs catalyst and then hydrogenation (Figure 10). An alternative strategy could 
involve the conjugate addition of organozinc reagents to enones (Figure 11), as al-
ready mentioned in scheme 23. 
Figure 9. CTP with different functional group 
 
29 
We categorized the disconnection by designating the number of atoms in the side 
of the amino acid as “c”, and the number of atoms in the reaction partner as “m”, 
so in a process involving cross-metathesis the number of atoms in the side-chain of 
the product is given by “c” + “m” -2 (not as enene). In the conjugate addition reac-
tion, the number of atom in the side chain of the product is simply “c” + “m”. 
 
























One possible approach in the second strategy is the use of two non-natural side 
chains in a common cyclic tetrapeptide precursor. For example, cyclic tetrapeptide 
134 could be used in a Suzuki coupling80,81 with 2-iodo-1-methoxyindole derivatives 
136 or the organozinc reagent could be made from 135, followed by Negishi cross 










Figure 11. Retrosynthetic analysis for Aoda analogues via conjugate addition 
Scheme 24. Suzuki  and Negishi coupling 
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Hydroboration/Suzuki cross-coupling83 on the remaining alkene, using the bromo-
enone 139 as an electrophile, followed by hydrogenation, would give the desired 







In order to synthesis apicidin 1, cross-metathesis is another possible approach to 
modify the side chain, via reaction of compound 137 with 1-penten -3-one using 











Scheme 25. Hydroboration and Suzuki coupling of remaining alkene 
Scheme 26. Cross-metathesis of remaining alkene 
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Chapter 2: Analogues of Aoda  
2.1 Introduction 
The initial target was the synthesis of the unsaturated amino acids 131-133, the re-
quired key intermediates for synthesis of the planned analogues of 2-amino-8-oxo-
decanoic acid (Aoda), 2. This required the synthesis of the corresponding amino acid 





2.2 Results and Discussion 
2.2.1 Iodide synthesis 
2.2.1.1 Synthesis of iodide 140 
Iodide 140 was prepared by the literature method84,85 shown (Scheme 27). The 










Figure 12. Key amino acid derived organozinc intermediates 
Scheme 27. Preparation of iodide 140 from S-serine 
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2.2.1.2 Synthesis of iodide 141 
The key step to access iodide 141 is the chemoselective reduction of the carboxylic 
acid of Boc-S-aspartic acid 1-benzyl ester 147 to the corresponding primary alcohol 
149. Previous work in the Jackson group86 had shown that this could be achieved in 
two steps via activation of the acid as an N-hydroxy-succinimide ester followed by 
reduction with NaBH4, in 59% yield. A recent report
87 described an alternative 
method in which the mixed anhydride 148 was reduced using NaBH4 to give alcohol 
149. The yield reported on small scale 0.33 mmol was 94%, and we achieved 86% 
on a larger scale (20 mmol) (Scheme 28). This latter method was preferred because 
of the shorter reaction time and better yield compared to activation via the            
N-hydroxy-succinimide ester. In the anhydride forming reaction it is important to 
maintain a temperature between -15 and -20 oC. Iodination of 149 under Appel 
conditions was achieved according to the literature87 in good yield (67%, on a 23 













Scheme 28. Preparation of iodide 141 from S-protected aspartic acid 
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2.2.1.3 Synthesis of iodide 142 
In order to prepare compound 142, the carboxylic acid group at the α-position in 
glutamic acid 150 was protected as an ester. This can only be done by an indirect 
route, via ring-opening of the anhydride 151 (Scheme 29), according to a literature 
route.88 Although the yield was low and not optimized, it allowed the preparation of 






Reduction of 152 to the alcohol 154 was carried out in the same way as previously 
described for 147. Subsequent iodination of 154 was carried out to give compound 












Scheme 29. Preparation of compound 152 via anhydride 151 
Scheme 30. Preparation of iodide 142 from S-protected glutamic acid 
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2.2.2 Allylation of protected amino acid 
2.2.2.1 Synthesis of butenyl glycine 131 via zinc insertion 
The zinc reagent 127 was prepared using prior Jackson group methodology89 from 
protected iodoalanine 140, and then converted into  butenylglycine 131 75% yield 
by copper-catalyzed allylation (Scheme 31). Previously in the Jackson group 90 the 
same allylation was achieved in 65% yield using stoichiometric amount of 








2.2.2.2 Synthesis of pentenylglycine132 via zinc insertion 
Zinc insertion into iodide 141 required more vigorous conditions, so the reaction 
was heated to 35 oC for 35 minutes under ultrasonication. The organozinc reagent 
156 was added to a mixture of allyl chloride with CuBr.DMS catalyst at room tem-
perature to give 132 in 64% yield after column chromatography and HPLC (Scheme 
32), since column chromatography alone did not allow the isolation of a pure sam-














Interestingly, the 1H NMR spectrum of the product 132 showed a downfield shift of 
the NH signal on increasing the concentration (mmol/mL) (Figure 13), which is likely 















Figure 13. Influence of concentration on chemical shift of NH in compound 132 in CDCl3 
Scheme 32. Preparation of protected pentenyl glycine 132 
NH, δ = 4.9 
NH, δ = 5.02 
 
NH, δ = 5.05 
J = 8.3 
 
 NH, δ = 5.08 
J = 8.3 
 












B) 6 × 10-2  
C) 21 × 10-2    
D) 36 × 10-2  
 
37 
2.2.2.3 Synthesis of hexenylglycine 133 via zinc insertion 
Copper catalyzed reaction of the organozinc reagent 129 with allyl chloride, under 
the same conditions as used for 156 gave a modest yield of 133 (38% on a 3 mmol 
scale) (Scheme 33). Under analogous conditions, without sonication, a very similar 
yield of 133 37% was obtained; the mass balance was identified as the protonated 








With the three key starting materials 131-133 in hand, cross-metathesis with a se-
lection of enones was investigated using general conditions reported in the litera-
ture59. All the reactions were carried out under positive pressure of nitrogen, and 
dry degases dichloromethane was used as the solvent. 
2.2.3.1 Synthesis of 7-oxo amino acids 
In an initial reaction, compound 131 was subjected to cross-metathesis with            
1-penten-3-one in the presence of Grubbs 2nd generation catalyst (Scheme 34).    
Instead of the expected cross-metathesis product, the pyrrolidine 159 was isolated 
after column chromatography. Compound 159 had the same molecular mass, but 
quite different 13C NMR spectrum from that expected for the target molecule (a 
peak corresponding to a saturated ketone appeared). In the 1H NMR spectrum, the 
peak for the olefinic protons disappeared and IR confirmed the absence of an NH 
group. This suggested that, an intramolecular aza-Michael reaction had taken place, 
to form the pyrrolidine derivative 159.  
Scheme 33. Preparation of protected hexenyl glycine 133 
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It is worth mentioning, that during purification a large amount of silica gel (133 gm 
for 0.4 mmol reacting product) was used and for an extended period (4.5 hr.). It 
therefore appeared that cyclisation occurred during purification. To minimize highly 
coloured ruthenium by product (in few cases) after 7 hr. reflux, DMSO was added to 





The initial 1H NMR spectroscopy data showed two sets of signals. When the spec-
trum was recorded at higher temperature, it became clear that rotamers were pre-














Figure 14. Rotameric behaviour of cross-metathesis product 159b, in DMSO. 
Scheme 34. Cross-metathesis and intramolecular aza-Michael reaction for compound 131 
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Recrystallization of the sample of pyrrolidine 159b gave crystals suitable for X-ray 
diffraction analysis. This showed that the product was indeed the pyrrolidine, as ex-
pected, and of trans-configuration (Figure 15). Since we were concerned that this 
stereoisomer may have preferentially crystallized, the 1H NMR spectrum of the spe-
cific crystal used for X-ray analysis was recorded. Although the concentration was 
low, it is clear that the spectrum matched closely that of the bulk compound with its 

















Figure 16. Comparison of 
1
H NMR of compound 159b recorded at r.t.; trans configuration, CDCl3 
 
Cross-metathesis of 131 with 1-hexen-3-one 160, followed by slow purification by 
column chromatography, gave the pyrrolidine 161b (87%) (Scheme 35). Compound 
161b was assigned as the trans diastereoisomer by comparing its 1H NMR spectrum 









H NMR for crystalline material  
H6α, H6α rotamer 





























2.2.3.1.1 Double protection of amine 
Since the initial cross-metathesis product appeared to be cyclizing during purifica-
tion, we explored double protection of the amine. Compound 131 was therefore 







Figure 17. Comparison of 
1
H NMR spectra of compound 161b with trans diastereoisomer 159b in DMSO 100 
o
C 
Scheme 36. Double protection of nitrogen atom in compound 131 
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Compound 162 was subjected to cross metathesis with different enones, in the pre-
cence of Grubbs 2nd generation catalyst. Modest yields of expected products 163-
165 were obtained (Scheme 37). The low yield may be due to the absence of a free 
NH or the steric hindrance due to the presence of the second Boc group but the re-
actions were not optimized. While this did allow the isolation of the initially target-







We decided to reinvestigate the use of the monoprotected derivative 131. When 
the reaction was repeated purification was carried out using less silica gel (31 gm 
for 0.4 mmol reacting product) and more quickly (30 min), the desired cross-
metathesis products 166-169 were isolated without any evidence of the pyrroli-
dines (Scheme 38), which suggested that it was indeed the prolonged exposure to 






Scheme 37. Cross-metathesis reaction of compound 162 
Scheme 38. Cross-metathesis reaction of compound 131, from mono N-protected serine 
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2.2.3.2 Synthesis of 8-oxo amino acids 
Reaction of protected pentenyl glycine 132, with 1-buten-3-one, 1-penten-3-one 
and 1-hexen-3-one in the presence of Grubbs 2nd generation catalyst, under stand-







Interestingly, when the reaction with 1-hexen-3-one was repeated, and the product 
was purified slowly using a large silica gel column, small amounts of the cyclized 
products 173a/b were isolated along with 172 (Scheme 40). After in-depth NMR 
analysis, the structure of these by products was assigned as the piperidine 173a/b.         
It was not possible at this stage to identify which stereoisomer was cis and which 
was trans. Subsequently the configurations were assigned to the two isomeric     








Scheme 39. Cross-metathesis reactions of compound 132, from protected aspartic acid 
Scheme 40. CM and intramolecular aza-Michael reaction 
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According to m/z (ES+) homodimers of 131-133 were found in the crude reaction 
mixture as expected. To better understand if the homodimer itself could be reacting 
with enone to generate products, another test reaction was carried out. When the 
alkene 132 was subjected to Grubbs 2nd generation catalyst in the absence of any 
enone, the homodimer 174 was isolated in excellent yield (98%). This was expected 
as, according to the literature,59 terminal alkenes such as 132 are shown to undergo 
rapid homodimerization. Subjection of 174 to the standard cross-metathesis condi-
tions with 1-hexen-3-one gave the expected product 172 (41%), together with re-
covered homodimer 174 (59%) (Scheme 41). Since the homodimer was not con-
sumed under the reaction condition used for the initial cross-metathesis, we can 
















Scheme 41. Homodimer pathway 
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2.2.3.3 Synthesis of 9-oxo amino acids 
 
Cross-metathesis of protected hexenyl glycine 133 proceeded smoothly giving the 
expected enones, 175-177 (Scheme 42). No evidence for the formation of 7-






2.2.4 Hydrogenation of cross-metathesis products 
With a range of enones available through cross-metathesis, the final step to prepare 
the target ω-oxoamino acids was hydrogenation.  Hydrogenation was carried out at 
1 atmosphere of H2 and room temperature, in the presence of 10% Pd/C catalyst 
(Scheme 43 & 44) and the results are shown in table 3. In the case of the benzyl es-









Scheme 42.  Cross-metathesis reactions of protected hexenyl glycine with different enone 
Scheme 43. Hydrogenation of enone and removing of benzyl group 
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In case of the methyl ester 166-168 and 175-177, the products were fully protected 

















Entry n Substrate R Products Yield % 
1 1 166 CH3 181 94 
2 1 167 C2H5 182 99 
3 1 168 C3H7 183 98 
4 3 175 CH3 184 94 
5 3 176 C2H5 185 99 
6 3 177 C3H7 186 99 




In conclusion we have shown that the cross-metathesis/hydrogenation, strategy is 
an efficient route for the synthesis of a wide range of Aoda analogues, and is        
arguably the most flexible route to this general class of compound. It was also       
established that cross-metathesis of the butenyl glycine derivative 131 can result in 
the formation of the pyrrolidines 159b and 161b, with high diastereoselectivity.      





















Chapter 3: Synthesis of pyrrolidine & piperidine derivatives 
3.1 Introduction: 
As discussed in chapter two cross-metathesis of the three key starting materials 
131-133 with a selection of enones gave the desired product, along with pyrrolidine 
by-products. Pyrrolidines, piperidines and their derivatives have emerged as im-
portant building blocks in the synthesis of natural products, biological active com-





The preparation of enantiomerically pure compounds is essential in medicinal 
chemistry as shown by the fact that absolute configuration of many pharmaceutical 
constituents has a significant role on their biological activity.101 With these factors in 
mind we decided to investigate further the stereoselective synthesis of pyrrolidine 
derivatives.  
There are many examples in the literature of the use of the aza-Michael reaction to 
give pyrrolidines and piperidines. For example, intramolecular aza-Michael reaction 
of amino enones using a combination of the amine catalyst I and TFA as a co-



















Yo and co-workers found that a catalytic amount of TFA promoted cyclisation of 
amino enons, so they suggested that using a chiral Brønsted acid could induce en-
antioselectivity. After optimisation, it was found that use of the binaph-
thylphosphoric acid II in toluene at -20 oC induced cyclisation of a variety of enone 
carbamates to give 2-substituted pyrrolidines in good yield and with high enantiose-












Scheme 45.  Synthesis of N-heterocycles using co-catalyst 
Scheme 46. Synthesis of pyrrolidines using phosphoric acid like a catalyst 
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Aza-Michael reaction can also be promoted using base. Cross-metathesis of the chi-
ral sulfinamide with methyl vinyl ketone in the presence of Ti(Oi-Pr)4 followed by 







A related cyclisation using tetrabutylammonium fluoride (TBAF) gave the cis prod-
uct in good yield and as a single diastereoisomer, while use of DBU gave the trans 
product (Scheme 48). Later when the trans diastereoisomer was treated with TBAF 
complete epimerization to the cis product was observed. Then established that the 














Scheme 47. Promote aza-Michael reaction by using base 
Scheme 48. Study on the thermodynamic/kinetic origin of cis and trans 
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In 2007, Fustero and co-workers104 reported the formation of 2,5-disubstituted    
pyrrolidines and 2,6-disubstituted piperidines using a tandem cross metathesis   in-
tramolecular aza-Michael reaction, catalyzed by a Hoveyda-Grubbs 2nd generation 
catalyst in the presence of BF3.OEt2 and promoted either by microwave irradiation 
or heat. This process gave high yields under both thermal and microwave conditions 
(Scheme 49). This paper provides a clear precedent for the cyclization reported in 
chapter two to give 159, 161 and 173a/b, although the conditions for our cycliza-











Subsequently Young et al.105,106 reported the use of an achiral Pd2+ complex and dif-
ferent Brønsted acids to selectively obtain either the cis or trans isomer of chiral 
nitrogen-containing heterocycles using the aza-Michael reaction. Other researchers 
have also reported that transition metals can catalyze aza-Michael reactions.11,107-109 
When Pd2+ complexes are used, it believed that the reaction can involve two path-
ways: either Pd2+, or a proton generated from hydrolysis of the transition metal 
complex, increases the Michael acceptor behavior of the enone.11,107,109,110 Strong 
Brønsted acids are recognized for their catalysis of aza-Michael additions by proto-
nation of the carbonyl of the enone, which increases its electrophilicity.111 The ini-
tial conclusion drawn was that the diastereoselectivity of reactions to generate ei-
ther cis or trans 3,5-disubstituted morpholines can be switched with different achi-









It was also found by Young et al.105 that introduction of bulkier groups as the R1 
substituent resulted in slightly better diastereoselectivity than when they were pre-
sent at the R2 position. This is due to the fact that the R1 substituent is closer to the 
point of ring formation, therefore allowing it to have more of an impact on the ste-
reochemical outcome (Scheme 50). In the case of R1 = CO2Me, the cis-isomer was 
the major product under both sets of conditions. When R1 = iPr and Cy, use of Pd2+ 
gave preferentially the cis-isomer, but use of TfOH gave the trans-isomer (Scheme 
46).  
Table 4. Diastereoselectivity comparison between Pd(MeCN)2Cl2 and TfOH -catalyst
105   
R1 R2 conditions Yield(%) d.r. (cis : trans) 




62 : 38 
76 : 24 




94 : 6 
14 : 86 




91 : 9 
11 : 89 
 
A. (MeCN)2PdCl2 (0.1 eq), B. TfOH (0.1 eq) 
 
Scheme 50. General Scheme for the Diastereoselective Synthesis of Morpholines X= O, n= 1 
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When the same conditions were applied by Young et al.105 to the substrate 192 ex-
cellent conversions were recorded, with moderate diasteroselectivity (Scheme 51). 





















Scheme 51. Young at el.  preparation 2,5-disubstituted pyrrolidines 
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3.2 Results and Discussion 
Our initial goal was to investigate cyclization more thoroughly when the cyclisation 
that we had observed occurred to give pyrrolidines. Since we had found conditions 
to prepare the enones 166-168, we initially stirred 166 with excess silica gel in the 
same solvent used for the purification. After purification of the product by chroma-
tography, a substantial amount of starting material (166, 66%) was recovered, along 
with an inseparable mixture of the pyrrolidines 193a and 193b (0.15 : 0.85) in 33% 
combined isolated yield (Scheme 52). The ratio of 193a to 193b was determined 
from 1H NMR spectroscopy. This result was quite distinct from the very high levels 
of diastereoselectivity observed previously (Chapter 2), and cast doubt on our per-










Given the literature precedent that the aza-Michael reaction can be catalysed by 
Brønsted acids, we considered that the cyclisation might be promoted by the NMR 
solvent, CDCl3. A crude sample of 166 (20 mg) appeared to be stable in CDCl3 (0.9 
mL) for 232 hr. However, when a purified sample of 166 (109 mg, 0.38 mmol) was 
subjected to the same condition, quantitative cyclisation to give the pyrrolidine 
193a/b (0.07 : 0.93) was observed (Scheme 53). Our conclusion therefore is that the 
cyclisation that we had observed previously (Chapter 2) was occurring after the 
Scheme 52. Cyclization of pure cross-metathesis product 166  using SiO2 
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NMR sample had been prepared, and before the spectrum was run; typically this 
delay was 2-18 hours. This means that a pure sample of enone 166 cyclised on 









3.2.1 Catalyst-induced cyclisation of cross-metathesis products 
3.2.1.1 Synthesis of  pyrrolidine derivatives 
 
Interestingly in two cases when a pure sample of enone was allowed to stand in 
CDCl3, no cyclisation was observed. Deliberate addition of HCl/Et2O then promoted 
cyclisation. In order to avoid the variability associated with different samples of 
CDCl3, it therefore appeared appropriate to investigate the use of HCl/Et2O for     
cyclisation. The enones 166-168 were separately treated with HCl/Et2O in dichloro-
methane (Scheme 54) and the results are shown in table 5. The diastereoisomer ra-
tio for compound 193a/b could be determined by 1H NMR, but not for 159a/b or 
161a/b. In this case GC was used, but it was established (entry 2) that both methods 
gave the same result for 193a/b. Comparison of the 1H NMR spectrum of the prod-
uct obtained by cyclization of 166 with that already determined for 159b and 161b, 
allowed the assignment of the stereochemistry of 193b as trans. 
 









Table 5. Obtained result of diastereoselective synthesis to 5-member ring 
entry Substrate R Product conversion *d.r. (cis : trans)  
1 166 CH3 193a/b 98.8 (1.2% SM) 0.06 : 0.94
a 
2 166 CH3 193a/b Complete  0.04 : 0.96
a,b 
3 167 C2H5 159a/b Complete  0.02 : 0.98
b 








 ratio determined with GC, * NMR of crude reaction mixture 
When compounds 166-168 were subjected to cyclization in the presence of a Pd2+ 
catalyst, the corresponding 2,5-pyrrolidine derivatives were formed (Scheme 55). In 
each case, a mixture of diastereoisomers was formed, and the ratio was determined 







Scheme 54. Acid catalyzed cyclization process 





The results show that the diastereoselectivity of the cyclization was in each case 
low. In the case of 166, the major diastereoisomer was the cis-compound 193a, but 
in the case of the two homologues 167, 168 there was either no diastereoselectivity 
or a very slight preference for the trans diastereosomer (Table 6). 
Table 6. Obtained result of 5-member ring by using Pd2+ 
R Catalyst (mol%) Product conversion *d.r. (cis : trans) 
CH3 25 193a/b Complete  0.66 : 0.34
b 
C2H5 11 159a/b // 0.5 : 0.5
b 




Ratio determined with GC, * NMR of crude reaction mixture 
Figure 19 shows a possible mechanism to account for the cyclisation reaction using 












Figure 19. General cyclization mechanism 
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Boc deprotection for each of the compounds 193, 159, 161 using trifluoroacetic acid 
(Scheme 56) gave 194-196. Fortunately the trifluoroacetate salts 194-196 were 
crystalline, and their structures are determined to be of trans configuration by X-ray 
diffraction (Figure 20). Since the structure of 159b had already been established as 
the trans-pyrrolidine, this demonstrated that the deprotection reaction had pro-
ceeded without influencing the stereochemistry this means that the assignments 


















Figure 20. Crystallography shown trans configuration 
Scheme 56. Boc deprotection to pyrrolidine 
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When cross-metathesis product 169 (Scheme 38, p42) was treated with 
bis(acetonitrile)dichloropalladium(II) in dry DCM, the isolated product was identi-
fied  as the vinylogous amide 197 (Scheme 57), whose structure was established by 
X-ray diffraction analysis (Figure 21).   













In the initial experiment three equal portions of catalyst (each 27 mole%) were add-
ed over a period of 70 hours. The product 197 was isolated in moderate yield (44%). 
When the reaction was repeated, but using less catalyst (11 mol%), the yield of 197 
dropped to (9%). This suggested that the reaction may in fact be stoichiometric in 
Pd2+. In an effort to re-oxidize the Pd2+ the reaction was conducted again (11 mol% 
Pd2+) open to the air, but the yield of 197 dropped further. Finally, use of a stoichi-
ometric amount of Pd2+ gave the product 197 in much higher yield (68%) (Table 7). 
When the crude compound or even a pure sample of compound 169 was dissolved 
in CDCl3, no cyclization was observed.  
Figure 21. X-ray structure for compound 197 
Scheme 57. Oxidative  cyclization of 169 
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Table 7. Cyclisation of using Pd2+ 
entry Catalyst (mol%) Yield 
1 81, added in 3 equal portions 44 
2 11 9 
3 11, open to the air 4.3 
4 Stoichiometric amount 68 
 
A suggested reaction mechanism showing cyclization followed β–hydride elimina-
tion is shown in figure 22. In principle, other appropriate oxidants might be capable 
















Figure 22. Cyclization & β- hydride elimination mechanism 
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3.2.1.2 Synthesis of  piperidine derivatives 
 
Treatment of the ethyl enone 171 with either (MeCN)2PdCl2 or HCl/Et2O each re-
sulted in cyclisation to give a separable mixture of the piperidines 198a and 198b. In 







Table 8. Obtained results to make compound 198 when different eq. of Pd2+  catalyst was  
                used 
Reaction Conditions Catalyst (mol%) Yield% *d.r. (cis : trans)  
A 125 99 0.74 : 0.26 
A 36 *Q 0.74 : 0.26 
A 14 *91 (9% SM) 0.66 : 0.34 
A 12 92 (4% SM) 0.7 : 0.3 
B 0.6 20 (79.5% SM) 0.83 : 0.17 
 
A : (MeCN)2PdCl2 mol%, dry DCM, 19 hr., r.t., under argon gas 
B : 1 M HCl/Et2O dry DCM 20 hr., r.t. 
Q = quantitative, SM = starting material, * NMR of the crude reaction mixture  
 
Scheme 58. Cyclization of cross-metathesis product by using Pd
2+ 
and Brønsted- acid catalysts 
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In order to elucidate the relative stereochemistry of products from the aza-Michael 
reaction, both purified diastereoisomers 198a and 198b were separately subjected 
to deprotection using trifluoroacetic acid (Scheme 59). Fortunately the trifluoroace-
tate salt 199 was crystalline, and its structure was determined to be cis by X-ray dif-
















Figure 23. X-ray structure of compound 199 
 
 
Scheme 59. N-Boc deprotection of 198a/198b 
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When compound 172 was subjected to cyclization conditions in the presence of 
Pd2+ catalyst (catalyst added in two equal portions each 11 mol% during 12 hr.) it 
gave two separable diastereoisomers 173a/b (Scheme 60). NMR of the crude reac-
tion mixture suggested that the isomers 173a and 173b had been formed in (0.62 : 
0.38) ratio, and the isolated yields of 173a and 173b were 40% and 24% respective-
ly. The close correlation between the diastereoisomers ratio determined from the 







When Boc deprotection was carried out for 173a (1 hr.) followed by basic work-up it 
gave a mixture of 201 and 173a, which suggests that the reaction time was not suf-
ficient. When the reaction time for deprotection of 173b was extended (from one 
hour to three hours) compound 202 was produced in excellent yield (Scheme 62). 
On the basis of the close precedent provided by the ethyl ketone 198a, we tenta-







Scheme 60. Cyclization of cross-metathesis product by using Pd
2+
 catalyst 
Scheme 61. N-Boc deprotection of 173a and neutralization 
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NOE studies were then performed to establish the relative stereochemistry. When 
H3 in compound 201 was irradiated, H7 was enhanced (C); irradiation of proton H7 
produced the expected nOe for proton H3 (Figures 24) (B), therefore nOe suggests 

































Scheme 62. N-Boc deprotection of 173b 
 
Since 201 was established to be of cis-configuration the implication is that 202 is the 
trans-isomer. This was confirmed by the close similarity of the 1H NMR spectra for 
compounds 202 and 200 (Figure 25). The configuration of 200 had already been de-
termined be trans, on the basis that the structure of the stereoisomer 199 was de-
















H NMR comparison of compounds 200 and 202 to show trans configuration 
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Treatment of the enone 170 with a catalytic amount of (MeCN)2PdCl2 under condi-
tions shown in scheme 63 gave a separable mixture of two diastereoisomeric piper-
idines 203a and 203b. NMR of the crude reaction mixture suggested that the iso-
mers 203a and 203b had been formed in a (0.74 : 0.26) ratio; the isolated yields of 
203a and 203b were 41% and 19% respectively. These were assigned as the cis and 
trans isomers on the basis of the close precedent provided by the ethyl ketone 
198a/b.  
 
When nOe studies were conducted on each of the separated isomers 203a and 
203b, no enhancements were observed. While this is the expected outcome for the 
trans-isomer, it suggests that the cis-isomer exist in a conformation in which the 2-
and 6- substituents exist in an axial conformation, therefore the two protons H3 and 








Figure 26. Suggested conformation of diastereoisomer 203a 



























Figure 27. NOE when H
7 
in compound 203a irradiated 
Figure 28. NOE when H
7 




We have identified a highly stereoselective cyclisation of Boc-protected amino ac-
ids, containing an enone in the side chain using HCl/Et2O leading to trans 2,5-
pyrrolidines in excellent yields and high diastereoselectivity; the Boc group results in 
much higher trans selectivity compared to the Z-protected analogues reported by 
























Chapter 4: Synthetic Approaches to Cyclic Tetrapeptides  
4.1 Introduction: 
With efficient routes both to the ω-oxoamino acids and a clear understanding of 
cross-metathesis and hydrogenation reactions needed for the side-chain of apicidin 







Solid-phase synthesis is a method in which the growing molecules are bound on an 
insoluble resin. This method was initially developed in the 1963 in order to synthe-
size peptides.112 In chapter one the synthesis of linear tetrapeptides (49, 57, 66) 
were described as precursors to chlamydocin 5,45 trapoxin 433 and analogues of 
natural apicidin 68.42 These peptides (Figure 30) were made by classical solution 






           
 
Figure 30. Linear tetrapeptides made by SPS 
Figure 29.  Natural apicidin and target molecule 
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One characteristic advantage of SPPS is that it enables the use of an excess of rea-
gents, in relation to the resin, to force the reaction to completion ensuring high 
yields in each step. Secondly, the work-up only includes filtration and washing to 
remove the excess of reagents and other soluble by-products.113 There is no need to 
purify the growing peptide sequence by chromatography until after it is cleaved 
from the resin, and therefore peptide synthesis can be automated. The downside to 
SPPS is that the resin is not soluble in most NMR solvents; therefore it makes analy-
sis of peptides on solid phase difficult, so only after cleavage from the resin is char-
acterization possible. Qualitative tests such as a ninhydrin test can show the success 
of the coupling by showing whether free amine group remain. In solution phase, 
intermediate purification is needed after each coupling to remove by-products and 
this has an impact on yield due to mechanical loss, and increasing the cost.114   
Since SPPS is more efficient we decided to use this approach to prepare the linear 
tetrapeptide precursor rather than solution phase synthesis.     
In addition there are two general approaches to SPPS- Fmoc and Boc (Figure 31); 
protecting group strategy (Boc or Fmoc) is important as it has a direct impact on 
cleavage conditions.114 In this project Fmoc protection method was preferred over 












The most important factor for resin selection is stability and loading capacity. The 2-
chlorotrityl chloride resin (2-ClTrt-Cl) resin was chosen because it is stable under the 
basic conditions used for Fmoc deprotection, and mild acidic conditions are re-
quired for release of the peptide sequence. The resin can help prevent formation of 
diketopiperazide during attachment of the first two amino acid, due to the steric 
bulk of 2-ClTrt-Cl group (Scheme 65) and also minimizes racemization during at-
tachment of the first amino acid113. Finally DMF is chosen as the solvent since it 
causes the resin to swell, allowing access to the growing peptide chain for the in-

















Scheme 65. Steric bulk to prevent diketopiperazide 
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Ring strain is one of the major difficulties in making cyclic tetrapeptides, with its rig-
id twelve atom backbones. Due to strong conjugation in peptide bonds, the trans 
conformation is favoured which makes it difficult for the amino and carboxyl termi-
ni to be in close geometric proximity to react, leading to tough activation conditions 
and long reaction times.17,114 Literature precedent116 suggests that slow cyclization 
rates enhance side reactions such as oligomerization. Turn inducing elements in the 
linear peptide are important in making small head to tail CTP,17 so in this project R-
proline was used since it is known to induce β-hairpin structures thus making the 
peptide cyclisation easer.  
In chapter one, the synthesis of the cyclic tetrapeptide 5 and 4 was described via 
formation of a bond between the C-terminus of the R-proline residue and the N-
terminus of the Aoe residue in the linear tetrapeptide 49 and 57. Therefore in this 
project cyclisation between the C-terminus of the R-proline residue and the N-
















4.2 Results and Discussion 
4.2.1 On resin linear tetrapeptide synthesis  
The key precursor for our planned peptide modification was the cyclic tetrapeptide 
210.  Three of the four residues were commercially available, and the fourth was 
easily prepared by hydrolysis of 132 (Scheme 66) using LiOH in (H2O : THF) to give 














The first step involves attachment of Fmoc-R-proline 4 eq. to the 2-ClTrt-Cl resin 
211 using N,N-diisopropylethylamine to neutralise the HCl produced. The solution 
was allowed to drain from the resin, which was then washed with mixture of (DCM/ 
MeOH/DIPEA), followed by DCM and DMF (Scheme 67). Fmoc deprotection of the 
residue in compound 212 was carried out using piperidine (25% in DMF) to generate 




Figure 32. Cyclic tetrapeptide 










Then subsequent additions to complete the required peptide sequence were car-
ried out using Fmoc-S-isoleucine, Fmoc-S-tryptophan and compound 209 under the 
same conditions, each time using 4 eq. of the protected amino acid. After each cou-
pling and Fmoc deprotection, washing was carried out with a series of solvents that 
allow the polymeric support to swell so any by-products that may have formed dur-
ing the coupling reaction were removed. HBTU was used as the coupling agent, 

















Scheme 67. Attaching first amino acid to the solid support 
Scheme 68. Growing amino acids on resin to make required sequence 
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Finally, the desired sequence was cleaved from the polymeric support using a mix-
ture of (AcOH/TFE/DCM) (2 : 2 : 6) containing a structure enhancing solvent TFE to 
increase β-hairpin conformation.117 The crude peptide solution was allowed to drain 
from the resin which was then washed with cleavage mixture, combined solution 
concentrated under reduced pressure  to give compound 216 in 31% overall yield 
after HPLC. Since we have four amino acids in the sequence one can assume an av-








The crude product 216 was purified by HPLC and the isolated fractions of retention 
times, tR= (2-4) = 216a, tR= (8-12) = 216b and tR= (13-14.5) = 216c.  According to  m/z 
(ES+) found the same M.wt to them; 216a = 662.3507, 216b = 662.3515 and 216c = 
640.3710 , but 216a/216b ionized by Na+ and 216c ionised by H+, of the three com-
pound isolated, 216c was the highest yield also it was purest according to 13C NMR 
and it was therefore chosen as the cyclisation substrate.  
m/z (ES+) data and NMR suggested isolation of three isomers of identical molecular 
weight however, since HBTU was used (a coupling reagent designed to avoid race-




Scheme 69. Detaching the peptide from the resin 
 
76 
Treating R-Pro-IIe-Trip-Boc-α-pentenyl glycine 216c with moderate strength acid, 
trifluoroacetic acid (TFA) in DCM gave 217 in quantitative yield (Scheme 70); in the 
presence of TIPS scavenger to avoid electrophilic aromatic substitution on the in-

























Scheme 70. Boc-deprotection 
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Cyclization of 217 was achieved between the C-terminus of the R-proline residue 
and N-terminus of the α-pentenyl glycine residue, via head-to-tail condensation by 
dropwise addition of LTP 217 to offer pseudo dilution to avoid homo dimerization. 
After purification of the crude product by HPLC beside the target molecule 210 
(16%), 218 (14%) was also isolated (Scheme 71) with no sign of homodimers in the 
crude reaction mixture even after checking the HPLC fractions by m/z (ES+). Howev-
er, the presence of 218 is evidence that dimerisation does happen, which then un-


























Compound 210 was subjected separately to cross metathesis reaction in two differ-
ent batches with 1-hexen-3-one and 1-buten-3-one. Rather than isolating the pre-
sumed enones 219 and 220 the crude products were each subjected to hydrogena-
tion. This allowed the isolation of the two cyclic peptides 221 (Figure 33) and 222 















































C for compound 221 
Figure 34. 
13




During the synthesis of linear tetrapeptides epimerization was identified as a prob-
lem in chain elongation on 2-ClTrt-Cl resin, with three isomers 216a-c isolated. Cy-
clisation of the linear tetrapeptide 216c using HATU as coupling agent gave the cy-
clic tetrapeptide 210 (16%), together with the cyclic octapeptide 218 (14%). Suc-
cessful modification of the side chain of the CTP 210 was achieved via cross-






















Our next target is making analogues of apicidin which incorporate α-epoxyketone 
and hydroxamic acid side chains. A possible route to introduce the epoxy ketone 
could be cross-metathesis/hydrogenation reaction between CTP 210 and the epox-






As already described in chapter one introduction of a hydroxamic acid group in the 
side chain to generate analogues of chlamydocin gave compound 10 with HDACi 
activity, so it would be interesting also to incorporate a hydroxamic acid in apicidin. 
In order to make the hydroxamic acid, cross-metathesis/hydrogenation of 210 with 
methyl acrylate 224, followed by conversion of the methyl ester to the hydroxamic 











Scheme 73. Analogue of apicidin including α-epoxyketone 
Scheme 74. Analogue of apicidin including hydroxamic acid 
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Chapter 5: Experimental 
5.1 General 
All moisture/air sensitive reactions were carried out under a nitrogen or argon at-
mosphere. All reagents used were purchased from commercial sources or prepared 
and purified accordingly by literature procedures. Iodide 140 was prepared by the 
literature method.84,85 Compounds 147 and 152 were purchased from Sigma-
Aldrich, or made by the literature method.88,118  furthermore Fmoc-R-proline, Fmoc-
S-isoleucine and Fmoc-S-tryptophan were purchased from Novabiochem VWR. Sol-
vents used were HPLC grade; all other dry solvents were obtained from the in-house 
Grubbs dry solvent system (model: SPS-200-6). Solvent evaporation under reduced 
pressure was performed using a Büchi rotary evaporator. Organic extracts were 
dried over MgSO4 or Na2SO4. Purification by column chromatography was per-
formed using silica gel for flash chromatography. Thin layer chromatography was 
performed using pre-coated plates, and compounds visualised by UV light (254 nm), 
ninhydrin solution (5% in MeOH).  
NMR spectra were recorded using Bruker AC 400 or Av III 400 or Bruker DRX 500. 
Coupling constants are given in Hertz to the nearest 0.1 Hz and were rationalized. 
13C NMR spectra were recorded at 100 MHz or 125 MHz. Optical rotations were 
measured on a Perkin Elmer 241 automatic polarimeter at λ 589 nm (Na, D-line) 
with a path length of 1 dm at 23 oC, the concentration is given in 10 mg/ml. Infra-
red spectra were recorded on a Perkin Elmer Paragon 100 FTIR spectrophotometer 
(νmax in cm
-1) as liquid films on sodium chloride plates. GC were recorded using col-
umn: Phenomenex ZB-5 (0.25 mm i.d. × 30 m., film thickness =250 µm.), oven tem-
perature = 145 oC isothermal; carrier gas: H2 at 1.4 mL/min.; injection: 250 
oC/split = 







5.2 General Procedure A: Reduction of carboxylic acid via anhy-
dride 
A two-necked round bottomed flask was charged with a magnetic stirrer bar then 
fitted with a dropping funnel equipped with a three-way tap on top and rubber sep-
tum on the other neck of the flask. It was flame-dried under vacuum and backfilled 
with nitrogen three times. The flask was allowed to cool, before adding N-Boc ami-
no acid (1.0 eq.) by rapid removal and replacement of the dropping funnel under a 
stream of nitrogen; then dry THF was added and the solution of N-Boc amino acid 
cooled to -15 oC to -20 oC. After 5 minutes, N-methylmorpholine (1.1 eq.) was added 
by syringe followed by dropwise addition of EtOCOCl (1.2 eq.) in THF and the reac-
tion stirred for 3 hr. at -15 oC to -20 oC. Then the reaction mixture was removed 
from the cooling bath and stirred for 20 minutes; then N-methylmorpholine hydro-
chloride was removed by filtration and washed with THF. The combined filtrate and 
washings were cooled to 0 oC and NaBH4 (specified in each experimental) was add-
ed immediately followed by drop wise addition of H2O (1 mL/1 mmol substrate). 
The reaction mixture was stirred at 0 oC for (1 hr.). The reaction was quenched by 
addition of saturated aqueous solution NH4Cl (4 mL/1 mmol substrate) and stirring 
was continued for 40 minutes at 0 oC. The reaction mixture was extracted with 
EtOAc (3 × 50 mL). The combined organic layers were washed with brine and dried 















General procedure A using 147 (6.4 g, 20 mmol, 1.0 eq.) in dry THF (60 mL) N-
methylmorpholine (2.4 mL, 22 mmol, 1.1 eq.), EtOCOCl (2.3 mL, 24 mmol, 1.2 eq.) in 
THF (20 mL), NaBH4 (1.3 g, 34 mmol, 1.7 eq.)  and H2O (20 mL), and then quenched 
by addition saturated aqueous solution NH4Cl gave benzyl (2S)-2-
([(tertbutoxy)carbonyl]amino)-4-hydroxybutanoate 149 as a white solid  (5.4 g, 17.4 
mmol, 86%). M.p./52-54 °C,    [α]D  -40.0 (c  0.1, MeOH), lit.
87: [α]D -40.2 (c 0.1, 
MeOH); Rf = 0.17 (30% EtOAc in petroleum ether); 
1H NMR (400 MHz, CDCl3) δ ppm: 
7.32-7.41 (5 H, m, Ph), 5.40 (1 H, br.d, J = 6.8 Hz, NH), 5.21 (1 H, d, J = 12.2 Hz, 
PhCHAHBCO2), 5.17 (1 H, d, J = 12.2 Hz, PhCH
AHBCO2), 4.50-4.59 (1 H, m, α–CH), 3.59 
-3.75 (2 H, m, CH2CH2OH), 2.12-2.24 (1 H, m, α-CHCH
AHBCH2), 1.57-1.67 (1 H, m, α-
CHCHAHBCH2), 1.45 (9 H, s, 
tBuO); 13C NMR (100 MHz, CDCl3) δ ppm: 172.7, 156.4, 
135.2, 128.6, 128.5, 128.3, 80.5, 67.3, 58.3, 50.7, 36.0, 28.3; m/z (ES+) found: 



















General procedure A using 152 (2.6 g, 10 mmol, 1.0 eq.) in dry THF (40 mL), N-
methylmorpholine (1.2 mL, 11 mmol, 1.1 eq.), EtOCOCl (1.14 mL, 12 mmol, 1.2 eq.) 
in THF (10 mL), NaBH4 (0.57 g, 15 mmol, 1.5 eq.) and H2O (10 mL), and then 
quenched by addition saturated aqueous solution NH4Cl  gave methyl (2S)-2-([(tert-
butoxy)carbonyl]amino)-5-hydroxypentanoate 154 as an oil  (1.97 g, 8 mmol, 80%). 
[α]D  +8.0 (c 1.0, CHCl3),  lit.
119 : [α]D +6.8 (c 0.98, CHCl3); Rf = 0.1 (30% EtOAc in petro-
leum ether); 1H NMR (400 MHz, CDCl3) δ ppm: 5.32 (1 H, br.d, J = 7.8, NH), 4.22-4.31 
(1 H, m, α-CH), 3.68 (3 H, s, OCH3), 3.59 (2 H, t,  J = 6.1, CH2OH), 1.78-1.89 (1 H , m, 
CHAHB), 1.63-1.74 (1 H ,m, CHAHB), 1.56 (2 H, quintet, J = 6.7 Hz, CH2CH2CH2), 1.41 (9 
H, s, tBuO); 13C NMR (100 MHz, CDCl3) δ ppm: 173.3, 155.6, 79.9, 61.7, 53.2, 52.2, 
29.3, 28.3, 28.2; IR (cm-1), 3356, 1735, 1710, 1523, 1172; m/z (ES+) found: 













5.3 General procedure B: Iodination of hydroxyl groups 
A two-necked round bottomed flask was charged with a magnetic stirrer bar then 
fitted with a three-way tap and rubber septum on the other neck of the flask. It was 
flame-dried under vacuum and backfilled with nitrogen three times. The flask was 
allowed to cool, before adding dry DCM (2 mL/1 mmol of substrate) by syringe; 
then triphenylphosphine (1.7 eq.) and imidazole (1.9 eq.) were added and stirred 
under nitrogen. The solution was cooled to 0 oC and then iodine (2.1 eq.) was added 
in three equal portions over 40 minutes then removed from the cooling bath and 
allowed to warm for 10 minutes and then the flask returned to ice-bath. A solution 
of amino alcohol (1 eq.) in dry CH2Cl2 (1 mL/1 mmol of substrate) was added slowly 
by syringe. After stirring for 7 hr. at 0 oC the reaction mixture was diluted with Et2O 
and stirring was continued at room temperature for (9 hr.). The residue was washed 
with aqueous solution of Na2S2O3 and brine then extracted with EtOAc and dried 
over Na2SO4. The solvent was removed under reduced pressure to give the crude 
product as yellow oil. Finally, the crude product was purified by silica gel column 
















General procedure B using triphenylphosphine (10.1 g, 38.4 mmol, 1.7 eq.), imidaz-
ole (2.9 g, 43 mmol, 1.9 eq.), iodine (12 g, 47.5 mmol, 2.1 eq.) and 149 (7 g, 22.6 
mmol, 1 eq.) gave benzyl (2S)-2-([(tert-butoxy)carbonyl]amino)-4-iodobutanoate 
141 as a white solid  (6.35 g, 15.2 mmol, 67%). M.p./55-56 °C, [α]D -30.0 (c 0.1, 
MeOH), lit.87: [α]D -32.4 ( c 0.1, MeOH); Rf = 0.42 (20% EtOAc in petroleumether); 
1H  
NMR (250 MHz, CDCl3) δ ppm: 7.33-7.41 (5 H, m, Ph), 5.22 (1 H, d , J = 12.2, Hz, 
PhCHAHBCO2), 5.16 (1 H, d, J = 12.2 Hz, PhCH
AHBCO2), 5.09 (1 H, d, J =7.5 Hz, NH), 
4.29-4.45 (1 H, m, α-CH), 3.08-3.19 (2H, m, CH2CH2I), 2.32-2.53 (1 H, m, CH2CH
AHBα-
CH), 2.09-2.29 (1 H, m, CH2CH
AHBα-CH), 1.45 (9 H, s, tBuO); 13C NMR (100 MHz, 
CDCl3) δ ppm: 171.4, 155.3, 135.1, 128.7, 128.6, 128.3, 80.3, 67.4, 54.4, 37.0, 28.3; 
IR (cm-1), 3374, 1742, 1720, 1502, 1168; m/z (ES+) found: 420.0667, C16H23NO4I re-





General procedure B using triphenylphosphine (9.27 g, 35.36 mmol, 1.7 eq.), imid-
azole (2.7 g, 39.5 mmol, 1.9 eq.), I2 (11.1 g, 43.68 mmol, 2.1 eq.) and 154 (5.16 g, 
20.8 mmol, 1.0 eq.) gave methyl (2S)-2-([(tert-butoxy)carbonyl]amino)-5-
iodopentanoate 142 as an oil  (3.8 g, 10.63 mmol, 51%). [α]D +22.7 (c 1.1, CHCl3); Rf  
= 0.4 (20% EtOAc in petroleum ether); 1H NMR (400 MHz, CDCl3) δ ppm: 5.08 (1 H, 
br.d, J = 8.1, NH), 4.26-4.35 (1 H, m, α-CH), 3.74 (3 H, s, OCH3), 3.12-3.23 (2 H, m, 
CH2I), 1.78-1.98 (3 H, m, CH
AHBCH2CH2), 1.65-1.76 (1 H, m, CH
AHB), 1.43 (9 H, s, 




5.4 General Procedure C: Allylation reactions                       A                                                         
A two-necked round bottomed flask was charged with a magnetic stirrer bar then 
fitted with a rubber septum and three-way tap. The flask was flame-dried under 
vacuum and backfilled with nitrogen three times. Zinc dust (2.5 eq. relative to alkyl 
iodide generally) was added, flame-dried and again evacuated and backfilled with 
nitrogen three times, with continuous stirring. The flask was allowed to cool, dry 
DMF (1 mL/1 mmol of alkyl iodide) was added via syringe, and the heterogeneous 
mixture stirred vigorously. Iodine (0.2 eq. relative to alkyl iodide generally) was 
added by rapid removal and replacement of the three-way tap under a stream of 
nitrogen, turning the solvent yellow. The mixture was stirred for 1-2 minutes, until 
the solvent had become a colourless. The alkyl iodide (1.0 mmol) was added by rap-
id removal and replacement of the three-way tap under a stream of nitrogen (in the 
case of compound 142 was dissolved in DMF and added by syringe via rubber sep-
tum). The mixture was stirred and an exotherm was observed stirring continued for 
a further 50 minutes at r.t. or 35-40 minutes at 35 oC with sonication; these details 
are specified with each example. The solid zinc dust was allowed to settle before 
transferring the solution containing the zinc reagent into a new reaction vessel via 
syringe. During the activation period, a separate two-necked round bottomed flask 
fitted with a magnetic stirrer bar, a rubber septum and three-way tap; was flame-
dried under vacuum and backfilled with nitrogen three times. It was allowed to 
cool, CuBr.DMS (0.1 eq. relative to alkyl iodide) was added and gently heated then 
evacuated and backfilled with nitrogen until the CuBr.DMS changed appearance 
from a grey-brown to light green powder. The flask was allowed to cool, before add-
ing dry DMF (0.6 mL/1 mmol of alkyl iodide) and allyl chloride (1.4 eq. relative to 
alkyl iodide generally) via syringe. The mixture was stirred at room temperature for 
about 5 minutes, at which point the organozinc reagent was added dropwise via 
syringe, and was stirred at room temperature for (3 hr.). The crude reaction mixture 










General procedure C using zinc dust (1.95 g, 30 mmol, 2.5 eq.), iodine (0.6 g, 2.4 
mmol, 0.2 eq.), 140 (3.94 g, 12 mmol, 1 eq.), CuBr.DMS (0.246 g, 1.2 mmol, 0.1 eq.), 
and allyl chloride (1.36 mL, 16.8 mmol, 1.4 eq.) gave methyl (2S)-2-([(tert-
butoxy)carbonyl]amino)hex-5-enoate 131 (2.2 g, 9 mmol, 75 %) as a colourless oil. 
Zinc insertion took 50 minutes at (r.t.). [α]D  -17.0 (c 1.0, MeOH), lit.
120: [α]D  -20.7 ( c  
0.97, MeOH); Rf = 0.57 (20% EtOAc in petroleum ether); 
1H NMR (400 MHz, CDCl3) δ 
ppm: 5.80 (1 H, ddt, J = 16.9, 10.3 and 6.6 Hz, CH2CH=CH2), 4.98-5.08 (3 H, m, NH, 
C=CH2), 4.28-4.37 (1 H, m, α-CH), 3.74 (3 H, s, CO2CH3), 2.06-2.17 (2 H, m, CH2C=C), 
1.85-1.96 (1 H, m, CHAHB), 1.65-1.77 (1 H, m, CHAHB), 1.44 (9 H, s, tBuO); 13C NMR 
(100 MHz, CDCl3) δ ppm: 173.3, 155.3, 136.9, 115.7, 79.8, 52.9, 52.3, 31.9, 29.5, 
28.3; IR (cm-1), 3370, 1742, 1712, 1516, 1451, 1365, 1254, 1168; m/z (ES+) found: 
















General procedure C using zinc dust (1.17 g, 18 mmol, 3 eq.), iodine (0.335 g, 1.32 
mmol, 0.22 eq.), 141 (2.5 g, 6 mmol, 1 eq.), CuBr.DMS (0.123 g, 0.6 mmol, 0.1 eq.), 
and allyl chloride (0.7 mL, 8.4 mmol, 1.4 eq.). Purification by column 
chromatography (20% EtOAc in petroleum ether) afforded the mixture of 
compound 132 and protonated zinc reagent 157 which was further purified by HPLC 
(XBridge Prep OBD C18 5µm 19 mmid x 250 mm), using 30 : 70 water/acetonitrile, 
at a flow rate of 17 mL.min-1 and UV detection at 210 nm, room temperature. The 
HPLC analysis showed a main peak tR = (8-10) that was identified as the target 
molecule benzyl (2S)-2-([(tert-butoxy)carbonyl]amino)hept-6-enoate 132 (1.28 g, 
3.8 mmol, 64% ) as a colourless oil. Zinc insertion took 35 minutes with sonication at 
35 oC. [α]D -4.0 (c 1, CHCl3), Rf = 0.54 (20% EtOAc in petroleum ether). 
1H NMR (400 
MHz, CDCl3) δ ppm: 7.31-7.40 (5 H, m, Ph), 5.72 (1 H, ddt, J = 16.9, 10.3 and 6.7 Hz,  
CH2CH=CH2), 5.22 (1 H, d, J = 12.4 Hz, PhCH
AHBCO2), 5.13 (1 H, d, J = 12.4 Hz, 
PhCHAHBCO2), 5.05 (1 H, d, J = 8.3 Hz, NH), 5.02-4.92 (2 H, m, CH=CH2), 4.30-4.39 (1 
H, m, α-CH), 1.96-2.12 (2 H, m, CH2CH2CH), 1.75-1.88 (1 H, m, CH
AHB), 1.58-1.69 (1 
H, m, CHAHB), 1.31-1.52 (11 H, m, CH2CH2CH2, 
tBuO).13C NMR (100 MHz, CDCl3) δ 
ppm: 172.7, 155.4, 137.9, 135.5, 128.6, 128.4, 128.2, 115.1, 79.8, 66.9, 53.4, 33.1, 
32.1, 28.3, 24.4; IR (cm-1), 3368, 1745, 1712, 1634, 1501, 1366, 1253, 1165, 1001, 
912; m/z (ES+) found: 334.2028, C19H28NO4 requires MH+ 334.2018.                             











General procedure C using zinc dust (487.5 mg, 7.5 mmol, 2.5 eq.), iodine (152.3 
mg, 0.6 mmol, 0.2 eq.), 142 (1100 mg, 3 mmol, 1 eq.),  CuBr.DMS (61.5 mg, 0.3 
mmol, 0.1 eq.), and allyl chloride (320 µl, 3.9 mmol, 1.3 eq.) gave methyl (2S)-2-
([(tert-butoxy)carbonyl]amino)oct-7-enoate 133 (311 mg, 1.15 mmol, 38%) as a col-
ourless oil. Zinc insertion took 40 minutes with sonication at 35 oC. [α]D -17.6 (c 
1.25, MeOH); Rf  = 0.52 (20% EtOAc in petroleum ether); 
1H NMR (400 MHz, CDCl3) δ 
ppm: 5.77 (1 H, ddt, J = 16.9, 10.1 and 6.8 Hz, CH2CH=CH2), 4.9-5.05 (3 H, m, 
CH=CH2, NH), 4.25-4.33 (1 H, m, α-CH), 3.73 (3 H, s, OCH3), 1.99-2.1 (2 H, m, 
CH2CH2CH=), 1.69-1.86 (1 H, m, CH
ACHB), 1.53-1.68 (1 H, m, CHACHB), 1.24-1.51 (4 H, 
m, C-CH2CH2-C), 1.44 (9 H, s, 
tBuO); 13C NMR (100 MHz, CDCl3) δ ppm: 173.4, 155.3, 
138.5, 114.6, 79.8, 53.3, 52.2, 33.4, 32.6, 28.4, 28.3, 24.6; IR (cm-1), 3370, 1745, 














5.5 Double protection to nitrogen of allylated products 




A mixture of mono Boc protected nitrogen of allylated product 131 (660 mg, 2.7 
mmol, 1 eq.), sodium hydride (60% in oil*, 97 mg, 4 mmol, 1.5 eq.), and di-tert-
butyl-dicarbonate (982 mg, 4.5 mmol, 1.66 eq.) in dry THF (25 mL) was stirred for 2 
days at reflux 66 oC. The reaction mixture allowed to cool, water was used to 
quench the reaction and the organic mixture extracted with CH2Cl2 (3 × 50 mL). The 
combined organic layers were washed with NaHCO3 (2 M), dried over sodium sul-
fate and solvent removed under reduce pressure. The crude product purify on silica 
gel column chromatography using gradient of 15-25% EtOAc in petroleum ether; 
gave methyl (2S)-2-(bis[(tert-butoxy)carbonyl]amino)hex-5-enoate 162 (650 mg, 
1.89 mmol, 70%) as an oil. Rf = 0.63 (20% EtOAc in petroleum ether); 
1H NMR (400 
MHz, CDCl3) δ ppm: 5.80 (1 H, ddt, J = 17.0, 10.3 and 6.5 Hz,  CH2CH=CH2), 5.04 (1 H, 
dq, J = 17.0 and 1.4 Hz, =CHH), 4.98 (1 H, br.dq, J = 10.3 and 1.5 Hz, =CHH), 4.87 (1 
H, dd, J =  9.3 and 5.1, α-CH), 3.71 (3 H, s, OCH3), 2.17-2.28 (1H, m, CHCH
AHBCH2), 
2.12 (2 H, q, J = 7.1 Hz,  CH2CH2CH), 1.91-2.03 (1 H, m, CHCH
AHBCH2), 1.49 (18 H, s, 2 
tBuO); 13C NMR (100 MHz, CDCl3) δ ppm: 171.4, 152.1, 137.4, 115.4, 83.1, 57.5, 
52.2, 30.3, 29.3, 27.9; IR (cm-1), 1748, 1705, 1458, 1371, 1251, 1128; m/z (ES+) 









5.6 General procedure D: Cross metathesis of unsaturated side 
chain amino acid 
A two-necked round bottomed flask was charged with a magnetic stirrer bar then 
fitted with a condenser equipped with a three-way tap on top and rubber septum 
on the other neck of the flask. It was flame-dried under vacuum and backfilled with 
nitrogen three times. The flask was allowed to cool, before adding allylic amino acid 
131-133 and enone in dry degassed DCM (2 mL) via syringe followed by adding 
Grubbs 2nd generation catalyst (5 mol% relative to substrate) in dry DCM (1 mL) 
were added by syringe. The reaction is heated at reflux for 7 hr., then the reaction 
mixture was concentrated and the residue was purified by column chromatography 





General procedure D using 162 (137.4 mg, 0.4 mmol, 1 eq.), vinyl methyl ketone 
(100 µl, 1.2 mmol, 3 eq.) and Grubbs 2nd generation catalyst (16 mg, 0.02 mmol, 5 
mol%) in CH2Cl2 (3 mL) gave methyl (2S,5E)-2-(bis[(tert-butoxy)carbonyl]amino)-7-
oxooct-5-enoate 163 (69 mg, 0.18 mmol, 44%) as an oil. [α]D -33.0 (c 0.73, CHCl3); Rf  
= 0.2 (20% EtOAc in petroleum ether); 1H NMR (400 MHz, CDCl3) δ ppm spectrum 
broadened due to rotomers: 6.72-6.82 (1 H, m, CH2CH=CH), 6.07 (1 H, d,  J = 15.9 
Hz, CH=CHCO), 4.84-4.89 (1 H, m, α–CH), 3.71 (1/2 H, OCH3), 3.70 (1/2 H, OCH3), 
2.25–2.36 (3 H, m, CH2CH2CH=, α-CHCH
AHBCH2), 2.23 (1/2 H, COCH3), 2.22 (1/2 H, 
COCH3), 1.98-2.13 (1 H, m, α-CHCH
AHBCH2), 1.48 (9 H, s, 
tBuO), 1.47 (9 H, s, tBuO); 
13C NMR (100 MHz, CDCl3) δ ppm: 198.4, 170.9, 152.1, 146.7, 131.8, 83.4, 57.5, 
52.3, 29.2, 28.6, 27.9, 26.8; IR (cm-1), 1747, 1697, 1678, 1366, 1252, 1144; m/z (ES+) 









General procedure D using 162 (137.4 mg, 0.4 mmol, 1 eq.), vinyl ethyl ketone (120 
µl, 1.2 mmol, 3 eq.) and Grubbs 2nd generation catalyst (16 mg, 0.02 mmol, 5 mol%) 
in CH2Cl2 (3 mL) gave methyl (2S,5E)-2-(bis[(tert-butoxy)carbonyl]amino)-7-oxonon-
5-enoate 164 (75 mg, 0.18 mmol, 46%) as an oil. [α]D -37.0 (c 1, CHCl3); Rf  = 0.38 
(20% EtOAc in petroleum ether); 1H NMR (500 MHz, CDCl3) δ ppm: 6.81 (1 H, dt, J = 
15.9 and 6.6  Hz, CH2CH=CH), 6.12 (1 H, d, J = 15.9 Hz CH=CHCO), 4.85-4.89 (1 H, m, 
α–CH), 3.72 (3 H, s, OCH3), 2.56 (2 H, q, J = 7.3 Hz, COCH2CH3),  2.24–2.35 (3 H, m, 
CH2CH2CH=, α-CHCH
AHBCH2), 1.99-2.12 (1 H, m, α-CHCH
AHBCH2), 1.49 (18 H, s, 2 
tBuO), 1.09 (3 H, t, J = 7.3 Hz, CH2CH3); 
13C NMR (125 MHz, CDCl3) δ ppm: 200.9, 
170.9, 152.1, 145.2, 130.6, 83.3, 57.5, 52.2, 33.2, 29.1, 28.6, 27.9, 8.0; IR (cm-1), 
1745, 1700, 1368, 1258, 1116; m/z (ES+) found: 400.2316, C20H34NO7 requires MH+ 
















General procedure D using 162 (137.4 mg, 0.4 mmol, 1 eq.), vinyl propyl ketone 
(140 µl, 1.2 mmol, 3 eq.) and Grubbs 2nd generation catalyst (16 mg, 0.02 mmol, 5 
mol %) in CH2Cl2 (3 mL) gave methyl (2S,5E)-2-(bis[(tert-butoxy)carbonyl]amino)-7-
oxodec-5-enoate 165 (88 mg, 0.21 mmol, 53%) as an oil. [α]D -32.0 (c 1, CHCl3); Rf  = 
0.4 (20 EtOAc in petroleum ether); 1H NMR (400 MHz, CDCl3) δ ppm: 6.80 (1 H, dt, J 
= 15.9 and 6.6 Hz, CH2CH=CH), 6.11 (1 H, d, J = 15.9 Hz, CH=CHCO), 4.84-4.9 (1 H, m, 
α–CH), 3.71 (3 H, s, OCH3), 2.51 (2 H, t, J = 7.3 Hz, COCH2CH2), 2.22–2.35 (3 H, m, 
CH2CH2CH=, α-CHCH
AHBCH2), 1.98-2.13 (1 H, m, α-CHCH
AHBCH2), 1.62 (2 H, sextet, J 
= 7.4 Hz, CH2CH2CH3), 1.49 (18 H, s, 2 
tBuO), 0.92 (3 H, t, J = 7.4 Hz, CH2CH3); 
13C 
NMR (100 MHz, CDCl3) δ ppm: 200.5, 170.9, 152.1, 145.4, 130.9, 83.4, 57.5, 52.3, 
41.9, 29.1, 28.6, 27.9, 17.6, 13.8; IR (cm-1), 1752, 1697, 1371, 1251, 1142; m/z (ES+) 
found: 436.2329, C21H35NO7Na requires MNa+
 436.2311. Homodimer of 162 was 
detected in the crude reaction mixture, m/z (ES+) found: 681.3608, C32H54N2O12Na 

















General procedure D using 131 (97 mg, 0.4 mmol, 1 eq.), vinyl methyl ketone (100 
µl, 1.2 mmol, 3 eq.) and Grubbs 2nd generation catalyst (16 mg, 0.02 mmol, 5 mol%) 
in CH2Cl2 (3 mL) gave methyl (2S, 5E)-2-([(tert-butoxy)carbonyl]amino)-7-oxooct-5-
enoate 166 (104 mg, 0.36 mmol, 91%) as an oil. [α]D  +40.0 (c 0.4, CHCl3); Rf  = 0.13 
(20% EtOAc in petroleum ether); 1H NMR (400 MHz, CDCl3) δ ppm: 6.77 (1 H, dt, J = 
16.0 and 6.7  Hz, CH2CH=CH), 6.09 (1 H, br.d, J = 16.0 Hz, CH=CHCO), 5.08 (1 H, d, J = 
8.1 Hz, NH), 4.30-4.42 (1H, m, α–CH), 3.76 (3 H, s, OCH3), 2.19–2.39 (2 H, m, 
CH2CH2CH=), 2.25 (3 H, s, COCH3), 1.92-2.11 (1 H, m, α-CHCH
AHBCH2), 1.74-1.86 (1 H, 
m, α-CHCHAHBCH2), 1.45 (9 H, s, 
tBuO); 13C NMR (100 MHz, CDCl3) δ ppm: 198.3, 
172.7, 155.3, 146.1, 131.9, 80.1, 52.8, 52.4, 31.3, 28.3, 28.2, 26.9; IR (cm-1), 3359, 
1749, 1715, 1673, 1518, 1450, 1371, 1253, 1166; m/z (ES+) found: 286.1648, 

















General procedure D using 131 (97 mg, 0.4 mmol, 1 eq.), vinyl ethyl ketone (120 µl, 
1.2 mmol, 3 eq.) and Grubbs 2nd generation catalyst (16 mg, 0.02 mmol, 5 mol%) in  
CH2Cl2 (3 mL) gave methyl (2S, 5E)-2-([(tert-butoxy)carbonyl]amino)-7-oxonon-5-
enoate 167 (110 mg, 0.37 mmol, 92%) as an oil. [α]D +36.4 (c  0.55, CHCl3); Rf  = 0.17 
(20% EtOAc in petroleum ether); 1H NMR (400 MHz, CDCl3) δ ppm: 6.76 (1 H, dt, J = 
15.8 and  6.8 Hz, CH2CH=CH), 6.09 (1 H, d, J = 15.8 Hz, CH=CHCO), 5.13 (1 H, d, J = 
7.6 Hz, NH), 4.25-4.36 (1 H, m, α–CH), 3.72 (3 H, s, OCH3), 2.53 (2 H, q, J = 7.3 Hz, 
COCH2CH3), 2.17–2.35 (2 H, m, CH2CH2CH=), 1.88-2.06 (1 H, m, α-CHCH
AHBCH2), 
1.71-1.82 (1 H, m, α-CHCHAHBCH2), 1.41 (9 H, s, 
tBuO), 1.06 (3 H, t, J = 7.3 Hz, 
CH2CH3); 
13C NMR (100 MHz, CDCl3) δ ppm: 200.7, 172.8, 155.3, 144.6, 130.7, 80.0, 
52.9, 52.4, 33.4, 31.3, 28.3, 28.2, 8.0; IR (cm-1), 3346, 1747, 1708, 1669, 1512, 1448, 















General procedure D using 131 (97 mg, 0.4 mmol, 1 eq.), vinyl propyl ketone (117 
µl, 1 mmol, 2.5 eq.) and Grubbs 2nd generation catalyst (16 mg, 0.02 mmol, 5 
mmol%) in CH2Cl2 (3 mL) gave methyl (2S,5E)-2-([(tert-butoxy)carbonyl]amino)-7-
oxodec-5-enoate 168 (113 mg, 0.36 mmol, 90%) as an oil. [α]D +30.7 (c 0.88, CHCl3); 
Rf  = 0.17 (20% EtOAc in petroleum ether); 
1H NMR (400 MHz, CDCl3) δ ppm: 6.78 (1 
H, dt, J = 15.8 and 6.8  Hz, CH2CH=CH), 6.11 (1 H, d, J = 15.8 Hz, CH=CHCO), 5.08 (1 
H, d, J =7.6 Hz, NH), 4.27-4.39 (1 H, m, α–CH), 3.75 (3 H, s, OCH3), 2.5 (2 H, t, J = 7.3 
Hz, COCH2CH2),  2.19–2.37 (2 H, m, CH2CH2CH=), 1.91-2.08 (1 H, m, α-CHCH
AHBCH2), 
1.69-1.85 (1 H, m, α-CHCHAHBCH2), 1.63 (2 H, sextet, J = 7.4 Hz, CH2CH2CH3), 1.44 (9 
H, s, tBuO), 0.93 (3 H, t, J = 7.5 Hz, CH2CH3);
 13C NMR (100 MHz, CDCl3) δ ppm: 200.4, 
172.8, 155.3, 144.7, 130.9, 80.1, 52.9, 52.4, 42.2, 31.3, 28.3, 28.2, 17.6, 13.8; IR (cm-
1), 3359, 1750, 1714, 1675, 1521, 1448, 1366, 1249, 1167; m/z (ES+) found: 
314.1889, C16H28NO5 requires MH+ 314.3940. Homodimer 102 was detected in the 















General procedure D using 131 (243 mg, 1 mmol, 1 eq.), methyl acrylate (271 µL, 3 
mmol, 3 eq.) and Grubbs 2nd generation catalyst (42 mg, 0.05 mmol, 5 mol%) in 
CH2Cl2 (3 mL) gave 1, 7-dimethyl (2E,6S)-6-([(tert-butoxy)carbonyl]amino)hept-2-
enedioate 169 (282 mg, 0.94 mmol, 93% yield) as an oil. [α]D +28.0 (c 1.25, CHCl3); Rf 
= 0.25 (20% EtOAc in petroleum ether); 1H NMR (400 MHz, CDCl3) δ ppm: 6.92 (1 H, 
dt, J = 15.5 and 6.9 Hz, CH2CH=CH), 5.84 (1 H, d, J = 15.5 Hz, CH=CHCO), 5.10 (1 H, d, 
J = 7.8 Hz, NH), 4.25-4.39 (1 H, m, α–CH), 3.74 (3 H, s, OCH3), 3.71 (3 H, s, OCH3), 
2.17–2.36 (2 H, m, CH2CH2CH=), 1.92-2.05 (1 H, m, α-CHCH
AHBCH2), 1.70-1.82 (1 H, 
m, α-CHCHAHBCH2), 1.43 (9 H, s, 
tBuO); 13C NMR (100 MHz, CDCl3) δ ppm:  172.8, 
166.8, 155.3, 147.3, 121.8, 80.1, 52.8, 52.4, 51.5, 31.2, 28.3, 28.0; IR (cm-1), 3364, 
1715, 1658, 1524, 1440, 1369, 1211, 1165; m/z (ES+) found: 302.1604, C14H24NO6 




















General procedure D using 132 (133.4 mg, 0.4 mmol, 1 eq.), vinyl methyl ketone 
(100 µl, 1.2 mmol, 3 eq.) and Grubbs 2nd generation catalyst (16 mg, 0.02 mmol, 5 
mol%) in  CH2Cl2 (3 mL) gave benzyl (2S,6E)-2-([(tert-butoxy)carbonyl]amino)-8-
oxonon-6-enoate 170 (134 mg, 0.36 mmol, 89%) as an oil. [α]D  -22.0 (c  0.91, 
MeOH); Rf  = 0.32 (30% EtOAc in petroleum ether); 
1H NMR (400 MHz, CDCl3) δ ppm: 
7.32-7.42 (5 H, m, Ph), 6.7 (1 H, dt, J = 16.0 and 6.9  Hz, CH2CH=CH), 6.04 (1 H, d, J = 
16.0 Hz, CH=CHCO), 5.22 (1 H, d, J = 12.2 Hz, PhCHAHBOCO), 5.14 (1 H, d, J = 12.2, 
Hz, PhCHAHBOCO), 5.05 (1 H, d, J = 8.1 Hz, NH), 4.33-4.41 (1 H, m, α–CH), 2.13-2.31 
(5 H, m, CH2CH2CH=,  COCH3), 1.77-1.91 (1 H, m, α-CHCH
AHBCH2), 1.59-1.72 (1 H, m, 
α-CHCHAHBCH2), 1.37-1.57 (2 H, m, CH
ACHBCH2CH2), 1.44 (9 H, s, 
tBuO); 13C NMR 
(100 MHz, CDCl3) δ ppm: 198.5, 172.5, 155.4, 147.1, 135.3, 131.6, 128.6, 128.5, 
128.3, 79.9, 67.1, 53.2, 32.3, 31.7, 28.3, 26.9, 23.7; IR (cm-1), 3342, 1715, 1694, 





















General procedure D using 132 (134 mg, 0.4 mmol, 1 eq.), vinyl ethyl ketone (200 
µl, 2 mmol, 5 eq.) and Grubbs 2nd generation catalyst (16 mg, 0.02 mmol, 5 mol%) in 
CH2Cl2 (3 mL) gave benzyl (2S,6E)-2-([(tert-butoxy)carbonyl]amino)-8-oxodec-6-
enoate 171 (141 mg, 0.36 mmol, 90%) as an oil. [α]D -19.5 (c  0.77, MeOH); Rf  = 0.18 
in ( 15% EtOAc in petroleum ether); 1H NMR (400 MHz, CDCl3) δ ppm: 7.30-7.39 (5 
H, m, Ph), 6.72 (1 H, dt, J = 16.0 and 6.8  Hz, CH2CH=CH), 6.05 (1 H, br.d, J = 16.0 Hz, 
CH=CHCO), 5.21 (1 H, d, J = 12.2 Hz, PhCHAHBOCO), 5.13 (1 H, d, J = 12.2 Hz, 
PhCHAHBOCO), 5.08 (1 H, d, J = 8.3 Hz, NH), 4.30-4.40 (1 H, m, α–CH), 2.52 (2 H, q, J 
= 7.3 Hz, COCH2CH3), 2.11-2.27 (2 H, m, CH2CH2CH=), 1.77-1.89 (1 H, m, α-
CHCHAHBCH2), 1.58-1.71 (1 H, m, α-CHCH
AHBCH2), 1.36-1.56 (11 H, m, 
CHACHBCH2CH2,  
tBuO), 1.10 (3 H, t, J = 7.3 Hz, CH2CH3); 
13C NMR (100 MHz, CDCl3) δ  
ppm: 200.8, 172.4, 155.4, 145.6, 135.3, 130.4, 128.6, 128.4, 128.3, 79.8, 67.1, 53.2, 
33.3, 32.2, 31.7, 28.3, 23.7, 8.1; IR (cm-1), 3362, 1741, 1696, 1673, 1629, 1499, 1248, 














General procedure D using 132 (133.4 mg, 0.4 mmol, 1 eq.), vinyl propyl ketone 
(117 µl, 1 mmol, 2.5 eq.) and Grubbs 2nd generation catalyst (16 mg, 0.02 mmol, 5 
mol%) in CH2Cl2  gave benzyl (2S,6E)-2-([(tert-butoxy)carbonyl]amino)-8-oxoundec-
6-enoate 172 (140 mg, 0.35 mmol, 86%) as an oil. [α]D -30.0 (c 0.1, MeOH); Rf  = 0.22 
(15% EtOAc in petroleum ether); 1H NMR (400 MHz, CDCl3) δ ppm: 7.33-7.41 (5 H, 
m, Ph),  6.73 (1 H, dt, J = 16.0 and 6.8 Hz, CH2CH=CH), 6.06 (1 H, br.d, J = 16.0, 
CH=CHCO), 5.22 (1 H, d, J = 12.2 Hz, PhCHAHBO), 5.14 (1 H, d, J = 12.2 Hz, 
PhCHAHBO), 5.04 (1 H, br.d, J = 8.3 Hz, NH), 4.32-4.42 (1 H, m, α–CH), 2.48 (2 H, t, J = 
7.32 Hz, COCH2CH2),  2.13-2.27 (2 H, m, CH2CH2CH=), 1.78-1.91 (1 H, m, CH
ACHB), 
1.57-1.71 (3 H, m, CHAHB, CH2CH2CH3), 1.37-1.56 (11 H, m, CH
AHBCH2CH2, 
tBuO), 
0.93 (3 H, t, J = 7.5 Hz, CH2CH3); 
13C NMR (100 MHz, CDCl3) δ ppm: 200.6, 172.5, 
155.5, 145.7, 135.3, 130.7, 128.6, 128.5, 128.3, 80.2, 67.1, 53.2, 42.1, 32.3, 31.7, 
28.3, 23.7, 17.6, 13.8; IR (cm-1), 3357, 1747, 1712, 1675, 1629, 1499, 1457, 1365, 



















The title compound (presumed to be E, but this was not confirmed) was synthesised 
using general procedure D, with benzyl (2S)-2-([(tert-butoxy)carbonyl]amino)hept-
6-enoate 132 (110 mg, 0.33 mmol, 1 eq.) as the starting material and grubbs 2nd 
generation catalyst (14 mg, 0.016 mmol, 5 mmol%), gave compound 174 (104 mg, 
0.163 mmol, 98%) as an oil. [α]D -1.3 (c 1.5, CHCl3); Rf = 0.3 (20% EtOAc in petroleum 
ether); 1H NMR (400 MHz,CDCl3) δ ppm: 7.29-7.40 (10 H, m, 2 Ph), 5.25-5.36 (2 H, 
m, CH=CH), 5.21 (2 H, d, J = 12.5 Hz, PhCHAHBCO2), 5.12 (2 H, d, J = 12.5 Hz, 
PhCHAHBCO2), 4.99-5.01 (2 H, m, NH), 4.27-4.43 (2 H, m, α-CH), 1.87-2.08 (4 H, m, 
CH2CH2CH), 1.72-1.86 (2 H, m, α-CHCH
AHBCH2), 1.54-1.71 (2 H, m, α-CHCH
AHBCH2), 
1.19-1.52 (4 H, m, CH2CH2CH2), 1.44 (18 H, s, 
tBuO); 13C NMR (100 MHz, CDCl3) δ 
ppm: 172.8, 155.4, 135.5, 130.1, 128.6, 128.4, 128.3, 79.8, 66.9, 53.5,  32.5, 31.9, 
28.3, 25.0;  IR (cm-1), 3370, 1745, 1717, 1501, 1459, 1250, 1163; m/z (ES+) found: 




















General procedure D using 133 (108.5 mg, 0.4 mmol, 1 eq.), vinyl methyl ketone (85 
µl, 1 mmol, 2.5 eq.) and Grubbs 2nd generation catalyst (16 mg, 0.02 mmol, 5 mol%) 
in CH2Cl2 (3 mL) gave methyl (2S,7E)-2-([(tert-butoxy)carbonyl]amino)-9-oxodec-7-
enoate 175 (103 mg, 0.33 mmol, 82%) as an oil. [α]D +20.0 (c 0.95, CHCl3); Rf  = 0.25 
(30% EtOAc in petroleum ether); 1H NMR (400 MHz, CDCl3) δ ppm: 6.76 (1 H, dt, J = 
16.0 and 6.9  Hz, CH2CH=CH ), 6.05 (1 H, d, J = 16.0 Hz, CH=CHCO), 5.04 (1H, br.d, J = 
8.1 Hz, NH), 4.24-4.34 (1 H, m, α–CH), 3.73 (3 H, s, OCH3), 2.17-2.26 (2 H, m, 
CH2CH2CH=), 2.23 (3 H, s, COCH3), 1.75-1.87 (1 H, m, α-CHCH
AHBCH2), 1.56-1.68 (1 H, 
m, α-CHCHAHBCH2), 1.29-1.55 (4 H, m, CH
ACHBCH2CH2), 1.43 ( 9 H, s, 
tBuO); 13C NMR 
(100 MHz, CDCl3) δ ppm: 198.6, 173.2, 155.3, 147.7, 131.5, 79.9, 53.2, 52.3, 32.5, 
32.1, 28.3, 27.6, 26.9, 24.8; IR (cm-1), 3356, 1749, 1717, 1674, 1523, 1441, 1369, 
1258, 1164; m/z (ES+) found: 314.1956, C16H28NO5 requires MH+ 314.1967, Ho-
modimer of 133 was detected in the crude reaction mixture, m/z (ES+) found: 



















General procedure D using 133 (108.5 mg, 0.4 mmol, 1 eq.), vinyl ethyl ketone (100 
µl, 1 mmol, 2.5 eq.) and Grubbs 2nd generation catalyst (16 mg, 0.02 mmol, 5 mol %) 
in CH2Cl2 (3 mL) gave methyl (2S,7E)-2-([(tert-butoxy)carbonyl]amino)-9-oxoundec-
7-enoate 176 (108 mg, 0.33 mmol, 82%) as an oil. [α]D  +23.7 (c  0.93, CHCl3); Rf  = 
0.22 (20% EtOAc in petroleum ether); 1H NMR (500 MHz, CDCl3) δ ppm: 6.79 (1 H, 
dt,  J = 16.0 and 6.9 Hz, CH2CH=CH), 6.08 (1 H, br.d, J = 16.0 Hz, CH=CHCO), 5.02 (1 
H, br.d, J = 7.5 Hz, NH), 4.25-4.34 (1 H, m, α–CH), 3.74 (3 H, s, OCH3), 2.55 (2 H, q, J = 
7.3 Hz, COCH2CH3), 2.21 (2 H, dq, J = 1.3 and 7.2 Hz, CH2CH2CH=), 1.73-1.87 (1 H, m, 
α-CHCHAHBCH2), 1.58-1.68 (1 H, m, α-CHCH
AHBCH2), 1.28-1.55 (4 H, m, 
CHACHBCH2CH2CH2), 1.44 (9 H, s, 
tBuO), 1.09 (3 H, t, J =7.3 Hz, CH2CH3); 
13C NMR 
(125 MHz, CDCl3) δ ppm: 201.0, 173.2, 155.3, 146.2, 130.2, 79.9, 53.2, 52.2, 33.2, 
32.5, 32.1, 28.3, 27.6, 24.8, 8.1; IR (cm-1), 3357, 1746, 1715, 1634, 1674, 1514, 1460, 




















General procedure D using 133 (108.5 mg, 0.4 mmol, 1 eq.), vinyl propyl ketone 
(117 µl, 1 mmol, 2.5 eq.) and Grubbs 2nd generation catalyst (16 mg, 0.02 mmol, 5 
mol%) in CH2Cl2 (3 mL) gave methyl (2S,7E)-2-([(tert-butoxy)carbonyl]amino)-9-
oxododec-7-enoate 177 (125.4 mg, 0.37 mmol, 91%) as an oil. [α]D +13.2 (c  0.38, 
CHCl3); Rf  = 0.29 (20% EtOAc in petroleum ether); 
1H NMR (400 MHz, CDCl3) δ ppm: 
6.77 (1 H, dt, J = 16.0 and 6.9 Hz, CH2CH=CH ), 6.07 (1 H, br.d, J = 16.0 Hz, 
CH=CHCO), 5.04 (1 H, br. d, J = 8.3 Hz, NH), 4.24-4.32 (1 H, m, α–CH), 3.72 (3 H, s, 
OCH3), 2.49 (2 H, t, J = 7.3 Hz, COCH2CH2), 2.19 (2 H, dq, J = 7.2 and 1.3 Hz, 
CH2CH2CH=), 1.74-1.85 (1 H, m, α-CHCH
AHBCH2), 1.56-1.67 (3 H, m, α-CHCH
AHBCH2, 
CH2CH2CH3), 1.27-1.54 (4 H, m, CH
ACHBCH2CH2CH2), 1.42 (9 H, s, 
tBuO), 0.92 (3 H, t, J 
= 7.5 Hz, CH2CH3);
 13C NMR (100 MHz, CDCl3) δ ppm: 200.7, 173.3, 155.3, 146.4, 
130.5, 79.9, 53.2, 52.2, 42.1, 32.5, 32.1, 28.3, 27.6, 24.8, 17.7, 13.8; IR (cm-1), 3357, 
1750, 1718, 1671, 1516, 1437, 1369, 1247, 1167; m/z (ES+) found: 342.2269, 














5.7 General Procedure E: Hydrogenation of cross-metathesis 
product 
A two-necked round bottomed flask with magnetic stirrer bar was fitted with a rub-
ber septum and three-way tap, and was flame-dried under vacuum and back-filled 
with nitrogen three times. The flask was allowed to cool, palladium on carbon cata-
lyst (10% w/w) (1 eq.) but in case of compounds [178-180] (1.5 eq.) was added to 
the flask which was evacuated and back-filled with nitrogen three times. Then ni-
trogen gas line replaced with balloon of hydrogen gas, cross-metathesis product (1 
eq.) was added to the flask as a solution in ethyl acetate (7 mL) via syringe. The flask 
was evacuated until the reaction mixture began to boil, and then back-filled with 
hydrogen gas. This procedure was repeated three more times, and the reaction 
stirred at room temperature for 1 day. To remove the catalyst the mixture was 
eluted through Celite® and then washed with EtOAc. The filtrate and washings were 
combined then the solvent removed under reduced pressure. No further purifica-
tion was required.  
 




General procedure E using 170 (50 mg, 0.133 mmol, 1 eq.) gave (2S)-2-([(tert-
butoxy)carbonyl]amino)-8-oxononanoic acid 178 (34 mg, 0.12 mmol 90%) as a col-
ourless oil. [α]D +5.0 (c 1.0, CHCl3); Rf  = 0.17 (EtOAc : petroleum ether : acetic acid, 5 
: 5 : 0.1 mL); 1H NMR (400 MHz, CDCl3) δ ppm: 5.02 (1 H, d, J = 7.8 Hz, α–CHNHCO), 
4.25-4.35 (1 H, m, α–CH), 2.44 (2 H, t, J = 7.3 Hz, CH2CH2CO), 2.14 (3 H, s, COCH3), 
1.79-1.93 (1 H, m, α-CHCHAHBCH2), 1.63-1.74 (1 H, m, α-CHCH
AHBCH2), 1.58 (2 H, 
quintet, J = 7.5 Hz, CH2CH2CCO), 1.27-1.48 (4 H, m, CH
ACHBCH2CH2), 1.45 (9 H, s, 
tBuO);  13C NMR (400 MHz, CDCl3) δ ppm: 209.6, 176.9, 155.6, 80.1, 53.3, 43.5, 32.3, 
29.8, 28.6, 28.3, 25.0, 23.4. IR (cm-1), 3340, 1730, 1700, 1658, 1520, 1390, 1368, 
1252, 1167; m/z (ES+) found: 288.1806, C14H26NO5 requires MH+ 288.1811 
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General procedure E using 171 (52 mg, 0.134 mmol, 1 eq.) gave (2S)-2-([(tert-
butoxy)carbonyl]amino)-8-oxodecanoic acid 179 (35 mg, 0.12 mmol, 89%) as a col-
ourless oil. [α]D -37.2 (c 0.94, CHCl3); Rf  =  0.28 (EtOAc : petroleum ether : acetic ac-
id, 5 : 5 : 0.1 mL); 1H NMR (400 MHz, CDCl3) δ ppm: 5.02 (1 H, d, J = 8.0 Hz, α–
CHNHCO), 4.24-4.35 (1 H, m, α–CH), 2.42 (2 H, q, J = 7.3 Hz, COCH2CH3), 2.41  (2 H, t, 
J = 7.3 Hz, CH2CH2CO), 1.79-1.92 (1 H, m, α-CHCH
AHBCH2),  1.63-1.74 (1 H, m, α-
CHCHAHBCH2), 1.58 (2 H, quintet, J = 7.3 Hz, CH2CH2CCO), 1.27-1.48 (4 H, m, 
CHACHBCH2CH2), 1.45 (9 H, s, 
tBuO), 1.05 (3 H, t, J = 7.3 Hz, CH2CH3); 
13C NMR (100 
MHz, CDCl3) δ ppm: 212.1, 176.9, 155.6, 80.2, 53.3, 42.1, 35.9, 32.2, 28.7, 28.3, 25.1, 
23.5, 7.8; IR (cm-1), 3322, 1735, 1713, 1681, 1510, 1460, 1395, 1249, 1166; m/z 
(ES+) found: 302.1953, C15H28NO5 requires MH+ 302.1967. 




General procedure E using 172 (82 mg, 0.2 mmol, 1 eq.) gave (2S)-2-([(tert-
butoxy)carbonyl]amino)-8-oxoundecanoic acid 180 (62 mg, 0.196 mmol, 98%) as a 
colourless oil. [α]D -16.0 (c 0.5, CHCl3); Rf  = 0.25 (EtOAc : petroleum ether : acetic 
acid, 5 : 5 : 0.1 mL); 1H NMR (400 MHz, CDCl3) δ ppm: 5.03 (1 H, d, J = 8.1 Hz, α–
CHNHCO), 4.24-4.35 (1 H, m, α–CH), 2.40 (2 H, t, J = 7.8 Hz, CH2COCH2), 2.38 (2 H, t, 
J = 7.5 Hz, CH2COCH2), 1.77-1.93 (1 H, m, α-CHCH
AHBCH2), 1.52-1.74 (5 H, m, α-
CHCHACHBCH2, CH2CH2CCO, CH2CH2CH3), 1.24-1.51 (4 H, m, CH
ACHBCH2CH2), 1.45 (9 
H, s, tBuO), 0.91 (3 H, t, J = 7.4 Hz, CH2CH3); 
13C NMR (100 MHz, CDCl3) δ ppm: 211.6, 
176.9, 155.6, 80.2, 53.3, 44.7, 42.5, 32.2, 28.7, 28.3, 25.1, 23.4, 17.3, 13.7; IR (cm-1), 
3346, 1717, 1701, 1688, 1511, 1453, 1366, 1243, 1159; m/z (ES+) found: 316.2119, 
C16H30NO5 requires MH+ 316.2124. 
 
109 




General procedure E using 166 (105 mg, 0.368 mmol, 1 eq.) gave methyl (2S)-2-
([(tert-butoxy)carbonyl]amino)-7-oxooctanoate 181 (100 mg, 0.348 mmol, 94%) as a 
colourless oil. [α]D +15.8 (c 0.95, CHCl3); Rf  = 0.31 (40% EtOAc in petroleum ether); 
1H NMR (400 MHz, CDCl3) δ ppm: 5.02 (1 H, d, J = 8.1 Hz, α–CHNHCO), 4.23-4.34 (1 
H, m, α–CH), 3.74 (3 H, s, OCH3), 2.43  (2 H, t, J = 7.2 Hz, CH2CH2CO), 2.13 (3 H, s, 
COCH3), 1.73-1.87 (1 H, m, α-CHCH
AHBCH2), 1.52-1.68 (3 H, m, α-CHCH
AHBCH2, 
CH2CH2CCO), 1.44 (9 H, s, 
tBuO), 1.22-1.40 (2 H, m, CHACHBCH2CH2); 
13C NMR (100 
MHz, CDCl3) δ ppm: 208.6, 173.3, 155.4, 79.8, 53.3, 52.3, 43.3, 32.5, 29.8, 28.3, 24.8, 
23.2; IR (cm-1), 3370, 1749, 1715, 1516, 1439, 1364, 1250, 1169; m/z (ES+) found: 





General procedure E using 167 (58 mg, 0.194 mmol, 1 eq.) gave methyl (2S)-2-
([(tert-butoxy)carbonyl]amino)-7-oxononanoate 182 (58 mg, 0.193 mmol, 99%) as a 
colourless oil. [α]D +16.0 (c 1, CHCl3); Rf  = 0.22 (20% EtOAc in petroleum ether); 
1H 
NMR (400 MHz, CDCl3) δ ppm: 5.03 (1 H, d, J = 8.1 Hz, α–CHNHCO), 4.21-4.31 (1 H, 
m, α–CH), 3.70 (3 H, s, OCH3), 2.34-2.43  (4 H, m, CH2CH2COCH2), 1.69-1.84 (1 H, m, 
α-CHCHAHBCH2), 1.50-1.66 (3 H, m, α-CHCH
AHBCH2, CH2CH2CCO), 1.42 (9 H, s, 
tBuO), 
1.22-1.37 (2 H, m, CHACHBCH2CH2), 1.02 (3 H, t, J = 7.3 Hz, CH2CH3); 
13C NMR (100 
MHz, CDCl3) δ ppm: 211.3, 173.3, 155.4, 79.8, 53.3, 52.2, 41.9, 35.9, 32.6, 28.3, 24.9, 
23.3, 7.8; IR (cm-1), 3360, 1751, 1712, 1519, 1455, 1370, 1256, 1167; m/z (ES+) 










General procedure E using 168 (89 mg, 0.284 mmol, 1 eq.) gave methyl (2S)-2-
([(tert-butoxy)carbonyl]amino)-7-oxodecanoate 183 (88 mg, 0.279 mmol, 98%) as 
colourless oil. [α]D +15.0 (c 2, CHCl3); Rf  = 0.46 (30% EtOAc in petroleum ether); 
1H 
NMR (400 MHz, CDCl3) δ ppm: 5.01 (1 H, d, J = 8.1 Hz, α–CHNHCO), 4.23-4.34 (1 H, 
m, α–CH), 3.73 (3 H, s, -OCH3), 2.39  (2 H, t, J = 7.3 Hz, COCH2), 2.36 (2 H, t, J = 7.3 
Hz, CH2CO), 1.71-1.87 (1 H, m, α-CHCH
AHBCH2), 1.51-1.67 (5 H, mα-CHCH
AHBCH2, 
CH2CH2CCO, CH2CH2CH3), 1.44 (9 H, s, 
tBuO), 1.24-1.39 (2 H, m, CHACHBCH2CH2), 
0.91 (3 H, t, J = 7.3 Hz, CH2CH3); 
13C NMR (100 MHz, CDCl3) δ ppm: 210.8, 173.3, 
155.4, 79.8, 53.3, 52.2, 44.7, 42.3, 32.6, 28.3, 24.9, 23.3, 17.3, 13.7; IR (cm-1), 3370, 
1749, 1715, 1514, 1454, 1367, 1250, 1170; m/z (ES+) found: 316.2134, C16H30NO5 






General procedure E using 175 (50 mg, 0.159 mmol, 1 eq.) gave methyl (2S)-2-
([(tert-butoxy)carbonyl]amino)-9-oxodecanoate 184 (47.5 mg, 0.15 mmol, 94%) as a 
colourless oil. [α]D +10.9 (c 1.1, CHCl3); Rf  = 0.17 (20% EtOAc in petroleum ether); 
1H 
NMR (500 MHz, CDCl3) δ ppm: 4.99 (1 H, br.d, J = 7.7 Hz, α–CHNHCO), 4.22-4.32 (1 
H, m, α–CH), 3.72 (3 H, s, OCH3), 2.39 (2 H, t, J = 7.4 Hz, CH2CH2CO), 2.12 (3 H , s, 
COCH3), 1.69-1.82 (1 H, m, α-CHCH
AHBCH2), 1.51-1.65 (3 H, m, α-CHCH
AHBCH2, CH2
7), 
1.43 (9 H, s, tBuO), 1.22-1.37 (6 H, m, CHAHBCH2CH2CH2); 
13C NMR (125 MHz, CDCl3) 
δ ppm: 209.1, 173.4, 155.3, 79.8, 53.3, 52.1, 43.6, 32.6,  29.8, 28.9, 28.8, 28.3, 25.0, 
23.6; IR (cm-1), 3365, 1745, 1712, 1516, 1438, 1370, 1249, 1164; m/z (ES+) found: 








General procedure E using 176 (49 mg, 0.15 mmol, 1 eq.) gave methyl (2S)-2-([(tert-
butoxy)carbonyl]amino)-9-oxoundecanoate 185 (49 mg, 0.148 mmol, 99%) as a col-
ourless oil. [α]D  +19.3 (c  0.68, CHCl3); Rf  = 0.27 (20% EtOAc in petroleum ether);     
1H NMR (400 MHz, CDCl3) δ ppm: 5.00 (1 H, br.d, J = 8.1 Hz, α–CHNHCO), 4.22-4.31 
(1 H, m, α–CH), 3.72 (3 H, s, OCH3), 2.34-2.44 (4 H, m, CH2CH2COCH2CH3), 1.69-1.82 
(1 H, m, α-CHCHAHBCH2),  1.49-1.65 (3 H, m, α-CHCH
AHBCH2, CH2
7), 1.43 (9 H, s, 
tBuO), 1.20-1.37 (6 H, m, CHACHBCH2CH2CH2), 1.03 (3 H, t, J = 7.3 Hz, CH2CH3);        
13C NMR (100 MHz, CDCl3) δ ppm: 211.7, 173.4, 155.3, 79.8, 53.3, 52.2, 42.2, 35.8,  
32.7, 28.9 (2 C), 28.3, 25.1, 23.7, 7.8; IR (cm-1), 3367, 1746, 1711, 1704, 1518, 1455, 





General procedure E using 177 (44 mg, 0.129 mmol, 1 eq.) gave methyl (2S)-2-
([(tert-butoxy)carbonyl]amino)-9-oxododecanoate 186 (44 mg, 0.128 mmol, 99%) as 
a colourless oil. [α]D  +14.1 (c  0.85, CHCl3); Rf  = 0.57 (30% EtOAc in petroleum 
ether); 1H NMR (400 MHz, CDCl3) δ ppm: 5.00 (1 H, br.d, J = 8.3 Hz, α–CHNHCO), 
4.23-4.33 (1 H, m, α–CH), 3.73 (3 H, s, OCH3), 2.37 (2 H, t, J = 7.3, COCH2CH2), 2.36 (2 
H, t, J = 7.3, CH2CH2CO),  1.69-1.85 (1 H, m, α-CHCH
AHBCH2), 1.49-1.67 (5 H, m, α-
CHCHAHBCH2, CH2
7, CH2CH2CH3), 1.44 (9 H, s, 
tBuO), 1.21-1.37 (6 H, m, 
CHACHBCH2CH2CH2), 0.90 (3 H, t, J = 7.5 Hz, CH2CH3); 
13C NMR (100 MHz, CDCl3) δ 
ppm: 211.4, 173.4, 155.4, 79.8, 53.4, 52.2, 44.7, 42.7, 32.7, 28.9 (2 C), 28.3, 25.1, 
23.6, 17.3, 13.7; IR (cm-1), 3370, 1749, 1713, 1692, 1520, 1462, 1247, 1172; m/z 
(ES+) found: 344.2437, C18H34NO5 requires MH+ 344.2437. 
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5.8 General procedure F: Intramolecular aza-Michael reaction 
Method A. The cross-metathesis product (1 eq.) was dissolved in DCM (2 mL) and a 
solution of HCl in Et2O (1 M, 0.6 mol%) was added. After 19 hr. stirring the resulting 
solution was concentrated under reduced pressure to give pure diastereoselective 
product. 
Method B. A two-necked round bottomed flask with magnetic stirrer bar was fitted 
with rubber septum and three-way tap. The flask was flame-dried under vacuum 
and backfilled with nitrogen three times. The flask allowed to cool, (MeCN)2PdCl2 
(specified in each experimental) was added by rapid removal and replacement of 
the three-way tap under a stream of nitrogen. Then nitrogen gas line replaced with 
balloon of argon gas, then cross-metathesis product (1 eq.) in dry DCM (2 mL) was 
added by syringe, and stirring was continued for an additional (T hr.). The reaction 
mixture was then filtered using diethyl ether through a pad of silica to remove the 
catalyst. The resulting filtrate and washings were combined and then concentrated 
under reduced presure. In the case of 173a/b, 198a/b and 203a/b crude residue 
was purified by flash silica gel chromatography using a gradient of 15-30% EtOAc in 
petroleum ether. 
5.9 General procedure G: Boc deprotection of amino acids 
The N-Boc protected compound was dissolved in DCM (4 mL). Neat TFA (50 eq.) rel-
ative to the substrate was added and the reaction followed by TLC. The solvent re-
moved under reduced pressure and an aqueous solution of NaOH 1 M was used to 








dicarboxylate (193a) & 1-tert-butyl 2-methyl (2S,5S)-5-(2-





General procedure F-A using methyl (2S,5E)-2-([(tert-butoxy)carbonyl]amino)-7-
oxooct-5-enoate  166 (32 mg, 0.112 mmol, 1 eq.) and 1 M HCl/Et2O (6.6 × 10
-4 
mmol, 0.66 µL, 0.6 mol%) in DCM (2 mL), after 19 hr. stirring at r.t. gave the title 
compounds 193a/b (32 mg, 0.11 mmol, 100%), as an oil, in a ratio of (0.04 cis 193a : 
0.96 trans 193b) based on GC and 1H NMR of the crude product in CDCl3 see next 
page. [α]D  -54.0 (c 1, CHCl3); Rf  = 0.19 (20% EtOAc in petroleum ether);
 1H NMR (500 
MHz, DMSO 100 oC) δ ppm: 4.14-4.23 (2 H, m, CHAHBCHCH2, COCHCH2),  3.65 (3 H, s, 
OCH3), 2.85 (1 H, br.d, J = 16.2 Hz, CHCH
AHBCO), 2.53 (1 H, dd, J = 16.2 and 9.7 Hz, 
CHCHAHBCO), 2.17-2.29 (1 H, m, COCHCHAHBCH2), 2.09 (3 H, s, COCH3), 1.95-2.06 (1 
H, m, CH2CH
AHBCHCH2), 1.78-1.85 (1 H, m, COCHCH
AHBCH2), 1.55-1.64 (1 H, m, 
CH2CH
AHBCHCH2), 1.36 (9 H, s, 
tBuO); 13C NMR (125 MHz, DMSO) δ ppm: 207.5 
(207.4), 173.5 (173.0), 153.1 (153.4), 79.5 (79.8), 59.4 (59.1), 54.1 (53.9), 52.3 
(52.2), 47.2 (48.1), 30.6 (30.7), 28.6 (29.3), 28.3 (28.4), 27.9 (27.1); IR (cm-1), 1752, 
1703, 1396, 1210, 1165, 1126; m/z (ES+) found: 286.1661, C14H24NO5 requires MH+ 
286.1654. In 13C NMR due to the rotamers, major isomer was reported and minor 








General procedure F-B using methyl (2S,5E)-2-([(tert-butoxy)carbonyl]amino)-7-
oxooct-5-enoate  166 (40 mg, 0.14 mmol, 1 eq.) and (CH3CN)2PdCl2 (9 mg, 0.035 
mmol, 0.25 eq.) in dry DCM (2 mL), after 19 hr. stirring at r.t. gave the title com-
pounds 193a/b (40 mg, 100%), as an oil, in a ratio of ( 0.66 cis : 0.34 trans) based on 
GC of the crude product. 
Different procedure: 
Methyl (2S,5E)-2-([(tert-butoxy)carbonyl]amino)-7-oxooct-5-enoate  166 (84 mg, 
0.29 mmol, 1 eq.) was added to silica gel (60 gm) in (20% EtOAc in petroleum ether) 
and stirred at room temperature for (90 hr.). Chromatography gave a mixture of 
193a/b (28 mg, 0.098 mmol, 33%), in a ratio of (0.15 cis : 0.85 trans) using a gradi-
ents of 20-30% EtOAc in petroleum ether.  
 
 
Significant signal for cis isomer in side mixture of two diastereoisomer when           




Significant signal for trans isomer in side mixture of two diastereoisomer when      












General procedure D using methyl (2S)-2-([(tert-butoxy)carbonyl]amino)hex-5-
enoate 131 (97 mg, 0.4 mmol, 1 eq.), vinyl ethyl ketone (100 µl, 1 mmol, 2.5 eq.) 
and Grubbs  2nd generation catalyst (16 mg, 0.02 mmol, 5 mol%) in CH2Cl2 (3 mL). 
Chromatography gave the title compound 159b (100 mg, 0.33 mmol, 83%) as an oil, 
then NMR sample was allowed to stand in CDCl3 and that all the subsequent charac-
terization was from that material.  
M.p./ 52-54 oC;  [α]D -50.5 (c 0.46, CHCl3); Rf  = 0.22 (20% EtOAc in petroleum ether); 
1H NMR (500 MHz, DMSO 100 oC) δ ppm: 4.22-4.16 (2 H, m, CH2CHCH
AHB, 
COCHCH2),  3.65 (3 H, s, OCH3), 2.84 (1 H, br.dd, J = 16.0 and 3 Hz, CHCH
AHBCO), 
2.52 (1 H, dd, J = 16.0 and 9.2 Hz, CHCHAHBCO ), 2.41 (2 H, q, J = 7.4 Hz, COCH2CH3), 
2.19-2.31 (1 H, m, COCHCHAHBCH2), 1.96-2.08 (1 H, m, CH2CH
AHBCHCH2), 1.78-1.85 
(1 H, m, COCH CHAHBCH2), 1.55-1.63 (1 H, m, CH2CH
AHBCHCH2), 1.36 (9 H, s, 
tBuO), 
0.96 (3 H, t, J = 7.3, CH2CH3); 
13C NMR (125 MHz, DMSO) δ ppm: 209.9 (209.8), 
173.5 (173.0), 153.1 (153.4), 79.5 (79.7), 59.4 (59.1), 54.2 (54.0), 52.3 (52.2), 46.0 
(46.7), 35.8 (35.9), 28.6 (29.3), 28.3 (28.4), 27.9 (27.1), 7.94 (7.98); IR (cm-1), 1745, 
1705, 1396, 1366, 1212, 1175, 1123; m/z (ES+) found: 300.1818, C15H26NO5 requires 
MH+ 300.1811. Homodimer of 131 was detected in the crude reaction mixture, m/z 
(ES+) found: 459.2697, C22H39N2O8 requires MH+ 459.2706. In 
13C NMR due to the 














General procedure F-A using methyl (2S,5E)-2-([(tert-butoxy)carbonyl]amino)-7-
oxonon-5-enoate 167 (30 mg, 0.1 mmol, 1 eq.) and 1 M HCl/Et2O (6 × 10
-4 mmol, 0.6 
µL,  0.6 mol%) in DCM (2 mL), after 19 hr. stirring at r.t. gave the title compounds 
159a/b (30 mg, 100%), in a ratio of (0.02 cis : 0.98 trans) based on GC of the crude 
product.  
General procedure F-B using of methyl (2S,5E)-2-([(tert-butoxy)carbonyl]amino)-7-
oxonon-5-enoate  167 (183 mg, 0.612 mmol, 1 eq.) and (CH3CN)2PdCl2 (18 mg, 0.07 
mmol, 0.11 eq.) in dry DCM (2 mL), after 19 hr. stirring at r.t. gave the title com-
pounds 159a/b (182 mg, 0.61 mmol, 99%),  in the ratio of (0.5 cis : 0.5 trans), based 


















General procedure D using methyl (2S)-2-([(tert-butoxy)carbonyl]amino)hex-5-
enoate 131 (97 mg, 0.4 mmol, 1 eq.), vinyl propyl ketone (117 µl, 1 mmol, 2.5 eq.) 
and Grubbs 2nd generation catalyst (16 mg, 0.02 mmol, 5 mol%) in CH2Cl2 (3 mL). 
Chromatography gave the title compounds 161b (110 mg, 0.351 mmol, 87%) as an 
oil and homodimer 102 (7 mg, 0.015 mmol, 7.6%). Then NMR sample was allowed 




[α]D -56.0 (c 1.25, CHCl3); Rf  = 0.18 (15% EtOAc in petroleum ether); 
1H NMR (500 
MHz, DMSO 100 oC) δ ppm: 4.15-4.22 (2 H, m, CH2CHCH
AHB, COCHCH2),  3.65 (3 H, s, 
OCH3), 2.84 (1 H, br.d, J = 16.1 Hz, CHCH
AHBCO), 2.52 (1 H, dd, J = 16.1 and 9.5 Hz, 
CHCHAHBCO), 2.38 (2 H, t, J = 7.3 Hz, COCH2CH2), 2.19-2.30 (1 H, m, 
COCHCHAHBCH2), 1.96-2.07 (1 H, m, CH2CH
AHBCHCH2), 1.78-1.86 (1 H, m, 
COCHCHAHBCH2), 1.56-1.64 (1 H, m, CH2CH
AHBCHCH2), 1.52 (2 H, sextet, J = 7.3 Hz, 
CH2CH2CH3), 1.36 (9 H, s, 
tBuO), 0.87 (3 H, t, J =7.4 Hz, CH2CH3); 
13C NMR (125 MHz, 
DMSO) δ ppm: 209.1 (209.0), 173.0 (172.6), 152.6 (152.9), 79.1 (79.3), 58.9 (58.7), 
53.7 (53.5), 51.8 (51.7), 45.8 (46.6), 44.2 (44.3), 28.2 (28.8), 27.8 (27.9), 27.5 (26.6), 
16.5 (16.6), 13.5 (13.4); IR (cm-1), 1751, 1699, 1392, 1258, 1085, 1020, 795; m/z 
(ES+) found: 314.1982, C16H28NO5 requires MH+ 314.1967. In 
13C NMR due to the 








Rf  = 0.07 (15% EtOAc in petroleum ether);  
1H NMR (400 MHz, CDCl3) δ ppm: 5.37-
5.48 (2 H, m, two olefinic proton), 5.01 (2 H, d, J = 8.8 Hz, 2 NH), 4.25-4.35 (2 H, m, 2 
α-CH), 3.74 (6 H, s, 2 CO2CH3), 1.97-2.14 (4 H, m, CH2CH=CH), 1.81-1.93 (2 H, m, 
CHAHB), 1.49-1.76 (2 H, m, CHAHB), 1.45 (18 H, s, 2 tBuO); 13C NMR (100 MHz, CDCl3) 
δ ppm: 173.3, 155.3, 137.3, 79.8, 52.9, 52.2, 32.4, 29.6, 28.3; m/z (ES+) found: 























General procedure F-A using methyl (2S,5E)-2-([(tert-butoxy)carbonyl]amino)-7-
oxodec-5-enoate 168 (49 mg, 0.16 mmol, 1 eq.) and 1 M HCl/Et2O (9 × 10
-4 mmol, 
0.9 µL, 0.6 mol%) in DCM (2 mL), after 19 hr. stirring at r.t. gave the title compounds 
161a/b  (49 mg, 0.16 mmol, 100%), as an oil, in a ratio of (0.02 cis : 0.98 trans) 
based on GC of the crude product.  
General procedure F-B using methyl (2S,5E)-2-([(tert-butoxy)carbonyl]amino)-7-
oxodec-5-enoate 168 (178 mg, 0.57 mmol, 1 eq.) and (CH3CN)2PdCl2 (16 mg, 0.062 
mmol, 0.11 eq.) in dry DCM (2 mL), after 19 hr. stirring at r.t. gave the title com-
pounds 161a/b (177 mg, 0.565 mmol, 99%), as oil, in a ratio of (0.45 cis : 0.55 trans), 
















General procedure F-B using 169 (90 mg, 0.3 mmol, 1 eq.) and three equal portions 
of the (MeCN)2PdCl2 (each 21 mg, 0.08 mmol, 27 mol%) was added, during 70 hr.; 
chromatography gave 1-tert-butyl 2-methyl (2S,5E)-5-2-methoxy-2-oxoethylidene) 
pyrrolidine-1,2-dicarboxylate 197 as a solid (40 mg, 0.132 mmol, 44%). M.p./ 63-67 
oC; [α]D +16.0 (c 0.25, CHCl3);  Rf  = 0.32 (20% EtOAc in petroleum ether); 
1H NMR 
(400 MHz, CDCl3) δ ppm: 6.53 (1 H, br.s, C=CHCO), 4.59 (1 H, dd, J = 9.3 and 3.2 
Hz,COCHCH2), 3.74 (3 H, s, OCH3), 3.65 (3 H, s, OCH3), 3.39 (1 H, dddd, J = 18.1, 9.1, 
3.6 and 1.7 Hz, CH2CH
AHBC), 2.96–3.09 (1 H, m, CH2CH
AHBC), 2.14-2.27 (1 H, m, 
CHCHAHBCH2), 1.96-2.05 (1 H, m, CHCH
AHBCH2), 1.46 (9 H, s,
tBuO); 13C NMR (100 
MHz, CDCl3) δ ppm: 172.2, 169.1, 156.7, 151.1, 96.5, 82.9, 62.1, 52.4, 50.8, 30.2, 
27.9, 25.4; IR (cm-1), 1753, 1733, 1623, 1438, 1380, 1136; m/z (ES+) found: 















General procedure G using 193 (88 mg, 0.31 mmol, 1 eq.) and TFA (1.2 mL, 15.5 
mmol, 50 eq.) gave (2S, 5S)-2-(methoxycarbonyl)-5-(2-oxopropyl)pyrrolidin-1-ium 
trifluoroacetate 194 (94 mg, 0.31 mmol, 100%) as solid. [α]D  -10.0 (c 1, CHCl3); Rf = 
0.075 (20% CHCl3, 30% petroleum ether and 50% acetonitrile), 
1H NMR (400 MHz, 
CDCl3) δ ppm: 4.48-4.75 (1 H, m, COCHCH2), 3.94-4.08 (1 H, m, CH2CHCH
AHB), 3.86 (3 
H, s, OCH3), 3.18-3.37 (1 H, m, CHCH
AHBCO), 2.93-3.13 (1 H, m, CHCHAHBCO), 2.53-
2.67 (1 H, m, COCHCHAHBCH2), 2.19-2.36 (1 H, m, CH2CH
AHBCHCH2), 2.22 (3 H, s, 
COCH3), 2.04-2.18 (1 H, m, COCHCH
AHBCH2), 1.85-2.00 (1 H, m, CH2CH
AHBCHCH2); 
13C NMR (100 MHz, CDCl3) δ ppm: 206.8, 169.7, 58.8, 57.1, 53.7, 44.1, 29.8, 29.5, 
27.8; IR (cm-1), 3425, 1751, 1715, 1676, 1445, 1366, 1245, 1185; m/z (ES+) found: 
186.1125, C9H16NO3

















General procedure G using 159 (43 mg, 0.144 mmol, 1 eq.) and TFA (0.55 mL, 7.2 
mmol, 50 eq.) gave (2S,5S)-2-(methoxycarbonyl)-5-(2-oxobutyl)pyrrolidin-1-ium tri-
fluoroacetate 195 (45 mg, 0.143 mmol, 99% yield) as solid. [α]D -6.1 (c 1.15, CHCl3); 
Rf = 0.125 (20% CHCl3, 30% petroleum ether and 50% acetonitrile);  
1H NMR (400 
MHz, CDCl3) δ ppm: 4.55-4.80 (1 H, m, COCHCH2), 3.92-4.04 (1 H, m, CH2CHCH
AHB), 
3.88 (3 H, s, OCH3), 3.22-3.38 (1 H, m, CHCH
AHBCO), 2.93-3.08 (1 H, m, CHCHAHBCO), 
2.60-2.72 (1 H, m, COCHCHAHBCH2), 2.41-2.59 (2 H, m, COCH2CH3), 2.21-2.35 (1 H, 
m, CH2CH
AHBCHCH2), 2.05-2.18 (1 H, m, COCHCH
AHBCH2), 1.91-2.05 (1 H, m, 
CH2CH
AHBCHCH2), 1.08 (3 H, t, J = 7.1 Hz, COCH2CH3); 
13C NMR (100 MHz, CDCl3) δ 
ppm: 209.2, 169.7, 58.7, 56.9, 53.7, 43.1, 35.7, 30.1, 27.9, 7.3; IR (cm-1), 1752, 1715, 
1674, 1446, 1246, 1203, 1176; m/z (ES+) found: 200.1293, C10H18NO3
+

















General procedure G using 161 (98 mg, 0.313 mmol, 1 eq.) and TFA (1.2 mL, 15.6 
mmol, 50 eq.) gave (2S, 5S)-2-(methoxycarbonyl)-5-(2-oxopentyl) pyrrolidin-1-ium 
trifluoroacetate 196 (100 mg, 0.31 mmol, 99% yield) as a solid. [α]D -2.0 (c 1, CHCl3); 
Rf = 0.15 (20% CHCl3, 30% petroleum ether and 50% acetonitrile); 
1H NMR (400 
MHz, CDCl3) δ ppm: 4.62 (1 H, t, J = 7.8 Hz COCHCH2), 3.89-4.04 (1 H, m, 
CH2CHCH
AHB), 3.87 (3 H, s, OCH3), 3.29 (1 H, dd, J = 18.7 and 9.1 Hz, CHCH
AHBCO), 
2.97 (1 H, dd, J = 18.7 and 3.8 Hz, CHCHAHBCO),  2.56-2.67 (1 H, m, COCHCHAHBCH2), 
2.35-2.55 (2 H, m, COCH2CH3), 2.20-2.34 (1 H, m, CH2CH
AHBCHCH2), 2.03-2.16 (1 H, 
m, COCH CHAHBCH2), 1.87-2.02 (1 H, m, CH2CH
AHBCHCH2), 1.62 (2 H, sextet, J = 7.3 
Hz, CH2CH2CH3), 0.92 (3 H, t, J = 7.3 Hz, COCH2CH3); 
13C NMR (100 MHz, CDCl3) δ 
ppm: 208.9, 169.7, 58.8, 57.2, 53.8, 44.4, 43.2, 29.9, 27.8, 16.8,  13.4; IR (cm-1), 
1749, 1715, 1674, 1446, 1246, 1203, 1176; m/z (ES+) found: 214.1439, C11H20NO3
+
             


















General procedure F-B using 170 (130 mg, 0.35 mmol, 1 eq.) and (CH3CN)2PdCl2  
catalyst (11 mg, 0.042 mmol, 0.12 eq.) in dry DCM . Chromatography gave 203a 
(54.5 mg, 0.145 mmol, 41%), and 203b (25 mg, 0.06 mmol, 19%). The ratio of (0.74 





[α]D -53.3 (c 1.8, CHCl3); Rf  = 0.27 (20% EtOAc in petroleum ether); 
1H NMR (400 
MHz, CDCl3) δ ppm: 7.30-7.40 (5 H, m, Ph), 5.19 (1 H, d, J = 12.0 Hz, PhCH
AHBO), 5.12 
(1 H, d, J = 12.0 Hz, PhCHAHBO), 4.63-4.97 (1 H, m,  COCHCH2), 4.53 -4.62 (1 H, m, 
CH2CHCH2), 2.47-2.85 (2 H, m, CHCH
AHBCO), 2.26 (1 H, d, J = 1.72 Hz, CH2CHCH
AHB), 
2.04 (3 H, s, COCH3), 1.18-1.73 (14 H, m, CH2CH2CH
AHB, tBuO); 13C NMR (100 MHz, 
CDCl3) δ ppm: 207.3, 172.8, 155.1, 135.5, 128.6, 128.4, 127.9, 80.3, 66.8, 53.4, 52.7, 
46.3, 30.2, 28.2, 27.5, 26.2, 15.5; IR (cm-1), 1741, 1712, 1696, 1366, 1171, 1073;  












[α]D -3.1 (c 0.65, CHCl3); Rf  = 0.16 (20% EtOAc in petroleum ether); 
1H NMR (400 
MHz, CDCl3) δ ppm: 7.29-7.37 (5 H, m, Ph), 5.21 (1 H, d, J = 12.0 Hz, PhCH
AHBO), 5.13 
(1 H, d, J =12.0 Hz, PhCHAHBO), 4.45-4.53 (1 H, m, CH2CHCH2), 4.22-4.39 (1 H, m, 
COCHCH2), 2.50-2.93 (2 H, m, CHCH
AHBCO), 2.17 (3 H, s, COCH3), 2.00-2.11 (1 H, m, 
CHAHBCH2CH2), 1.89-1.99 (1 H, m, CH
AHBCH2CH2), 1.76-1.89 (1 H, m, CH2CH2CH
AHB), 
1.48-1.65 (3 H, m, CH2CH2CH
AHB), 1.39 (9 H, s, tBuO); 13C NMR (100 MHz, CDCl3) δ 
ppm: 206.7, 172.7, 155.3, 135.7, 128.5, 128.4, 128.2, 80.6, 66.7, 54.3, 47.9, 47.7, 
30.1, 28.2, 24.8 (2 C), 14.7; IR (cm-1), 1745, 1696, 1366, 1256, 1168; m/z (ES+) 




















General procedure F-A using 171 (181 mg, 0.465 mmol, 1 eq.) and 1 M HCl/Et2O as a 
catalyst (3 × 10-3 mmol, 3 µl, 0.6 mol%.) in DCM (2 mL), after 19 hr. stirring at r.t.; 
chromatography gave 198a (30 mg, 0.077 mmol, 16.6%) as a colourless oil, and 
198b (6.5 mg, 0.017 mmol, 3.6%) as a colourless oil, also starting material (142 mg, 
0.365 mmol, 78.5%) recovered. The ratio of (0.83 cis : 0.17 trans) was determined 
by 1H NMR of the crude product. 
General procedure F-B using 171 (108 mg, 0.277 mmol, 1 eq.) and (CH3CN)2PdCl2  
catalyst (8.5 mg, 0.033 mmol, 0.12 eq.) in dry DCM (2 mL), after 19 hr. stirring at r.t.; 
chromatography gave 198a (68 mg, 0.175 mmol, 63%) as white solid, and 198b (31 
mg, 0.079 mmol, 29%) as a colourless oil, also starting material 171 (4.3 mg, 0.11 
mmol, 4%) recovered. The ratio of (0.7 cis : 0.3 trans) was determined by 1H NMR of 















[α]D -57.0 (c 0.65, CHCl3); Rf  = 0.44 (20% EtOAc in petroleum ether); 
1H NMR (400 
MHz, CDCl3) δ ppm: 7.29-7.41 (5 H, m, Ph), 5.19 (1 H, d, J = 12.0 Hz, PhCH
AHBO), 5.14 
(1 H, d, J = 12.0 Hz, PhCHAHBO), 4.66-4.99 (1 H, m, COCHCH2), 4.53-4.62 (1 H, m, 
CH2CHCH2), 2.62-2.85 (1 H, m, CHCH
AHBCO), 2.47-2.61 (1 H, m, CHCHAHBCO), 2.16-
2.46 (3 H, m, COCH2CH3, , CH2CH2CH
AHB), 1.28-1.75 (14 H, m, CH2CH2CH
AHB, tBuO),  
0.99 (3 H, t, J = 7.3 Hz, CH2CH3); 
13C NMR (100 MHz, CDCl3) δ ppm: 210.0, 172.8, 
155.1, 135.5, 128.6, 128.4 (2 C), 80.3, 66.8, 53.1, 46.6, 44.8, 36.2, 28.3, 27.6, 26.2, 
15.6, 7.7; IR (cm-1), 1748, 1715, 1698, 1375, 1178, 1078; m/z (ES+) found: 390.2297, 





[α]D  -4.0 (c 0.5, CHCl3); Rf  = 0.31 (20% EtOAc in petroleum ether); 
1H NMR (400 
MHz, CDCl3) δ ppm: 7.29-7.37 (5 H, m, Ph), 5.2 (1 H, d, J = 12.0 Hz, PhCH
AHBO), 5.14 
(1 H, d, J = 12.0 Hz, PhCHAHBO), 4.45-4.53 (1 H, m, CH2CHCH2), 4.23-4.39 (1 H, m, 
COCHCH2), 2.53-2.83 (2 H, m, CHCH
AHBCO), 2.47 (2 H, q, J = 7.3 Hz, COCH2CH3), 1.91-
2.12 (2 H, m, CH2CH2CH2), 1.76-1.89 (1 H, m, CH2CH2CH
AHB),  1.48-1.66 (3 H, m, 
CH2CH2CH
AHB),  1.40 ( 9 H, s, tBuO), 1.05 (3 H, t, J = 7.3 Hz, CH2CH3); 
13C NMR (100 
MHz, CDCl3) δ ppm: 209.3, 172.7, 155.3, 135.8, 128.5, 128.22 (2 C), 80.5, 66.7, 54.3, 
48.1, 46.3, 36.1, 28.3, 24.9 (2 C), 14.8, 7.7; IR (cm-1), 1745, 1696, 1391, 1369, 1170, 









General procedure F-B using 172 (110 mg, 0.273 mmol, 1 eq.) and two equal por-
tions of (CH3CN)2PdCl2 ( each 7.8 mg, 0.03 mmol, 11 mol%) in dry DCM (2 mL), after 
12 hr. stirring at r.t.; chromatography gave 173a (44 mg, 0.109 mmole, 40%) as a 
colourless oil and 173b (26.7 mg, 0.066 mmol, 24%) as a colourless oil. The ratio of 





[α] D  -50.0 (c 1.5, CHCl3); Rf  = 0.4 (20% EtOAc in petroleum ether); 
1H NMR (500 
MHz, CDCl3) δ ppm: 7.30-7.40 (5 H, m, Ph), 5.19 (1 H, d, J = 12.0 Hz, PhCH
AHBO), 5.14 
(1 H, d, J = 12.0 Hz, PhCHAHBO), 4.82 (1 H, br.s, COCHCH2), 4.53-4.63 (1 H, m, 
CH2CHCH2), 2.46-2.78 (2 H, m, COCH
AHBCH), 2.16-2.36 (3 H, m, COCH2CH2, 
CH2CH2CH
AHB), 1.27-1.76 (16 H, m, CH2CH2CH3, CH2CH2CH
AHB, tBuO),  0.87 (3 H, t, J = 
7.5 Hz, CH2CH3); 
13C NMR (125 MHz, CDCl3) δ ppm: 209.6, 172.8, 155.2, 135.5, 
128.6, 128.4 (2 C), 80.3, 66.8, 53.3, 52.8, 46.4, 44.9, 28.3, 27.5, 26.2, 17.2, 15.6, 
13.6; IR (cm-1), 1745, 1693, 1393, 1370, 1344, 1174, 1096; m/z (ES+) found: 
404.2417, C23H34NO5 requires MH+ 404.2437.                                                                                                                                      









[α]D +1.1 (c  0.95, CHCl3); Rf  = 0.33 (20% EtOAc in petroleum ether); 
1H NMR (400 
MHz, CDCl3) δ ppm: 7.28-7.39 (5 H, m, Ph), 5.21 (1 H, d, J = 12.0 Hz, PhCH
AHBCO), 
5.13 (1 H, d, J = 12.0 Hz, PhCHAHBCO), 4.44-4.54 (1 H, m, CH2CHCH
AHB), 4.19-4.38 (1 
H, m, COCHCH2), 2.52-2.85 (2 H, m, CHCH
AHBCO), 2.42 (2 H, t, J = 6.8 Hz, COCH2CH2), 
1.88-2.09 (2 H, m, CH2CH2CH2), 1.74-1.87 (1 H, m, CH2CH2CH
AHB), 1.48-1.69 (5 H, m, 
CH2CH2CH3, CH2CH2CH
AHB), 1.39 (9 H, s, tBuO), 0.90 (3 H, t, J = 7.5 Hz, CH2CH3); 
13C 
NMR (100 MHz, CDCl3) δ ppm: 208.9, 172.7, 155.3, 135.8, 128.5, 128.2 (2 C), 80.5, 
66.7, 54.3, 48.0, 46.5, 44.8, 28.3, 24.9, 24.8, 17.1, 14.8, 13.7; IR (cm-1), 1745, 1696, 



















General procedure G using 198a (97 mg, 0.24 mmol, 1 eq.), TFA (1.7 ml, 22.8 mmol, 
95 eq.), H2O (50 µl) and TIPS (20 µl). The crude product was purified by preparative 
HPLC (XBridge Prep OBD C18 5µm 19 mmid x 250 mm), using gradient from 95 : 5 to 
5 : 95 water/acetonitrile, (H2O contain 0.1% TFA) in 40 minutes, at a flow rate of 17 
mL. min-1 and UV detection at 210 nm. The HPLC analysis showed a main peak tR = 
(15-16) that was identified as the cis diastereoisomer, gave (2S,6R)-2-
[(benzyloxy)carbonyl]-6-(2-oxobutyl)piperidin-1-ium trifluoroacetate 199 (95 mg, 
0.23 mmol, 95%). M.p./ 127-138 oC; [α]D -20.0, (c 0.25, CHCl3); Rf  = 0.83 (40% MeOH 
in  EtOAc); 1H NMR (500 MHz, CDCl3) δ ppm: 7.27-7.41 (5 H, m, Ph), 5.21 (1 H, d, J = 
12.0 Hz, PhCHAHBO), 5.16 (1 H, d, J = 12.0 Hz, PhCHAHBO), 3.92 (1 H, br.d, J = 12.0 Hz, 
COCHCH2), 3.54-3.64 (1 H, m, CH2CHCH2), 3.26 (1 H, br.d, J = 17.6 Hz, CHCH
AHBCO), 
2.89-3.02 (1 H, m, CHCHAHBCO), 2.37-2.57 (2 H, m, COCH2CH3), 2.28 (1 H, br.d, J = 
13.5 Hz, CHAHBCH2CH2), 1.80-2.04 (3 H, m, CH
AHBCHAHBCHAHB), 1.57-1.72 (2 H, m, 
CH2, CH
AHBCHAHB), 1.01 (3 H, t, J = 7.1 Hz, CH2CH3); 
13C NMR (125 MHz, CDCl3) δ 
ppm: 209.1, 168.4, 134.3, 128.7 (2 C), 128.1, 68.0, 58.0, 53.6, 44.1, 36.2, 27.5, 25.8, 
22.4, 7.3; IR (cm-1), 1746, 1665, 1659, 1425, 1303, 1203; m/z (ES+) found: 290.1762, 
C17H24NO3













General procedure G using 198b (10 mg, 0.026 mmol, 1 eq.) and TFA (99 µl, 1.3 
mmol, 50 eq.). The crude product was purified by preparative HPLC (XBridge Prep 
OBD C18 5µm 19 mmid x 250 mm), using gradient from 95 : 5 to 5 : 95 wa-
ter/acetonitrile, (H2O contain 0.1% TFA) in 40 minutes, at a flow rate of 17 mL. min
-1 
and UV detection at 210 nm. The HPLC analysis showed a main peak tR = (16-18) 
that was identified as the trans diastereoisomer (2S, 6S)-2-[(benzyloxy)carbonyl]-6-
(2-oxobutyl) piperidin-1-ium trifluoroacetate 200 (9 mg, 0.023 mmol, 88%). [α]D  
+24.0 (c 0.25, CHCl3); Rf  = 0.73 (40% MeOH in EtOAc); 
1H NMR (500 MHz, CDCl3) δ 
ppm: 7.38 (5 H, s, Ph), 5.32 (1 H, d, J = 12.0 Hz, PhCHAHBO), 5.29 (1 H, d, J = 12.0 Hz, 
PhCHAHBO), 4.42-4.53 (1 H, m, COCHCH2), 3.65-3.75 (1 H, m, CH2CHCH2), 3.13-3.29 
(1 H, m, CHCHAHBCO), 2.71-2.82 (1 H, m, CHCHAHBCO), 2.40-2.63 (2 H, m, 
COCH2CH3), 2.29-2.38 (1 H, m, CH
AHBCH2CH2), 2.13 (1 H, t, J = 12.2 Hz,  
CHAHBCH2CH2), 1.69-1.84 (3 H, m, CH2CH2,CH
AHB), 1.27-1.39 (1 H, m, CH2CH2,CH
AHB), 
1.08 (3 H, t, J = 7.0 Hz, CH2CH3); 
13C NMR (125 MHz, CDCl3) δ ppm: 210.8, 168.2, 
134.3, 128.9, 128.7, 128.6, 68.5, 54.6, 50.5, 43.6, 36.1, 27.6, 23.8, 19.2, 7.3; IR (cm-
1), 3284, 1752, 1690, 1678, 1409, 1344, 1200, 1135; m/z (ES+) found: 290.1751, 
C17H24NO3















General procedure G using 173a (8.5 mg, 0.021 mmol, 1 eq.) and TFA (77 µl, 1 
mmol, 50 eq.), the reaction stirred for 1 hr. at room temperature. Then the solvent 
removed under reduced pressure, followed by base work-up by using 1 M NaOH, 
making pH = 12, after extraction with EtOAc (50 × 3 mL) gave benzyl (2S,6R)-6-(2-
oxopentyl)piperidine-2-carboxylate 201 (4 mg, 0.0132 mmol, 63%) and also starting 
material 173a (4 mg, 0.009 mmol). Purification was carried out by eluting over SiO2 
with 30-70% EtOAc in petroleum ether. [α]D  -40.0 (c 0.3, CHCl3); Rf  = 0.37 (30% pe-
troleum ether in EtOAc); 1H NMR (500 MHz, CDCl3) δ ppm: 7.29-7.38 (5 H, m, Ph), 
5.19 (1 H, d, J = 12.3 Hz, PhCHAHBO), 5.13 (1 H, d, J = 12.3 Hz, PhCHAHBO), 3.42-3.47 
(1 H, m, COCHCH2), 3.01-3.08 (1 H, m, CH2CHCH2), 2.59 (1 H, dd, J = 17.6 and 7.9 Hz, 
CHCHAHBCO), 2.52 (1 H, dd, J =  17.6 and 4.6 Hz, CHCHAHBCO), 2.38 (2 H, t, J = 7.3 Hz, 
COCH2CH2), 2.01-2.07 (1 H, m, CH
AHBCH2CH2), 1.84-1.91 (1 H, m, CH2CH
AHBCH2),  
1.60 (2 H, sextet, J = 7.4 Hz, CH2CH2CH3,), 1.53-1.59 (1 H, m, CH2CH2CH
AHB), 1.36-
1.49 (2 H, m, CHAHBCHAHBCH2), 1.08-1.19 (1 H, m, CH2CH2CH
AHB), 0.91 (3 H, t, J = 7.5 
Hz, CH2CH3); 
13C NMR (125 MHz, CDCl3) δ ppm: 210.2, 172.9, 135.7, 128.5, 128.2, 
128.1, 66.4, 58.9, 51.8, 49.3, 45.4, 31.5, 28.8, 24.2, 17.2, 13.7; IR (cm-1), 3582, 3336, 














General procedure G using 173b (13 mg, 0.032 mmol, 1 eq.) and TFA (122 µl, 1.6 
mmol, 50 eq.) to give ((2S, 6S)-2-[(benzyloxy)carbonyl]-6-(2-oxopentyl)piperidin-1-
ium trifluoroacetate 202 (13 mg, 0.031 mmol, 97%). [α]D +26.7 (c 0.6, CHCl3); Rf  = 
0.23 (40% MeOH in petroleum ether); 1H NMR (400 MHz, CDCl3) δ ppm: 7.36-7.40 
(5 H, m, Ph), 5.33 (1 H, d, J = 12.0 Hz, PhCHAHBO), 5.28 (1 H, d, J = 12.0 Hz, 
PhCHAHBO), 4.43-4.51 (1 H, m, COCHCH2), 3.64-3.76 (1 H, m, CH2CHCH2), 3.15 (1 H, 
dd, J = 19.0 and 9.8 Hz CHCHAHBCO), 2.76 (1 H, dd, J = 19.0 and 3.5 Hz CHCHAHBCO), 
2.37-2.54 (2 H, m, COCH2CH2), 2.28-2.38 (1 H, m, CH
AHBCH2CH2), 2.04-2.16 (1 H, m, 
CHAHBCH2CH2), 1.69-1.83 (3 H, m, CH2CH2CH
AHB), 1.62 (2 H, sextet, J = 7.3 Hz, 
CH2CH2CH3), 1.15-1.39 (1 H, m, CH2CH2CH
AHB), 0.92 (3 H, t, J = 7.5, CH2CH3); 
13C 
NMR (100 MHz, CDCl3) δ ppm: 210.3, 168.1, 134.3, 129.0, 128.8, 128.6, 68.5, 54.6, 
50.5, 44.7, 43.9, 27.5, 23.9, 19.1, 16.8, 13.5; IR (cm-1), 3414, 1746, 1678, 1591, 1415, 
1206, 1185, 1131; m/z (ES+) found: 304.1923, C18H26NO3













(2R)-1-[(2S,3S)-2-[(2S)-2-[(2S)-2-([(tert-butoxy)carbonyl]amino)               
hept-6-enamido]-3-(1H-indol-3-yl)propanamido]-3-     methylpenta-





A) Resin loading: 
The 2-ClTrt-Cl resin 1.42 mmol/g (211 mg, 0.3 mmol, 1 eq.) and DMF (3 mL) were 
placed in varian bond elut reservoir 20 mL on orbital shaker, for 7 hr., to get the res-
in swollen followed by washing with DCM (2 × 3 mL). A solution of Fmoc-R-pro-OH 
(405 mg, 1.2 mmol, 4 eq.) and DIPEA (315 μl, 1.8 mmol, 6 eq.) in dry DCM (3 mL) 
was added and the mixture was stirred overnight. Then the solution was allowed to 
drain from the resin which was washed with (DCM/MeOH/DIPEA) (3 × 3 mL) (17 : 2 : 
1) (7.65 : 0.9 : 0.45) mL and then with: DCM (3 × 3 mL), DMF (2 × 3 mL) and DCM (2 
× 3 mL), (1.5 min each). 
 
B) Fmoc deprotection:  
Fmoc-R-pro-O-2ClTrt-resin swollen in DMF (3 mL) for 1 hr., the Fmoc protecting 
group was carried out using piperidine (25%)  in DMF, (0.75 : 2.25), (3 mL, 1 × 5 
min), (3 mL, 1 × 30 minutes ); and then washings with DMF (2 × 3 mL), DCM (2 × 3 












C) Peptide synthesis protocol:  
The reaction was achieved by a coupling using HBTU in DMF as coupling reagent: 
DIPEA (367 µL, 2.1 mmol, 7 eq.) was added to Fmoc-S-isoleucine (424 mg, 1.2 mmol, 
4 eq.) in DMF (3 mL), and stirred for (1/2 minutes) then HBTU (455 mg, 1.2 mmol, 4 
eq.) was added and stirred for (5 minutes), the solution was loaded to the resin and 
stirred on orbital shaker for (3 hr.), then washing with: DCM (3 × 3 mL), DMF (2 × 3 
mL) and DCM (2 × 3 mL) (1.5 minutes  each). After each peptide coupling Fmoc de 
protection was done as in previous page mentioned. 
 2nd peptide coupling solution of Fmoc-S-tryptophan (512 mg, 1.2 mmol, 4 eq.), DMF 
(3 mL), DIPEA (367 µL, 2.1 mmol, 7 eq.) and HBTU (455 mg, 1.2 mmol, 4 eq.) was 
loaded, to the resin, followed by washing and Fmoc deprotection.  
3rd coupling N-Boc-α-pent-4-enyl glycine (291.7 mg, 1.2 mmol, 4 eq.), DMF (3 mL), 
DIPEA (367 µL, 2.1 mmol, 7 eq.) and HBTU (455 mg, 1.2 mmol, 4 eq.) was loaded to 
the resin, 2nd and 3rd coupling were done in similar way to Fmoc-S-isoleucine. 
 
D) Cleavage (2-ClTrt-Cl):  
The dried peptide resin was treated with cleavage mixture (AcOH/TFE/DCM) (2 : 2 : 
6) (10 μL × 1 mg of resin) for (2 hr.), under stirring. Then the solution was filtered off 
and the resin washed with neat cleavage mixture (2 ×3 mL) 1.5 minutes each. Then 
the combined solution concentrated under reduced pressure followed by adding 
hexane (15 times volume) to remove acetic acid as an azeotrope, the filtrate was 
concentrated and lyophilized, to give crude product (111 mg). It was purified by 
preparative HPLC (XBridge Prep OBD C18 5µm 19 mmid x 250 mm), using 50 : 50 
water/acetonitrile, at a flow rate of 17 mL. min-1 and UV detection at 254 nm. The 
HPLC analysis showed three main peaks tR= (2-4), (8-12) and (13-14.5) that were 
identified by electrospray mass spectrometry as the linear Boc tetrapeptides; 216a 
tR= (2-4) (7 mg, 0.011 mmol, 3.6% yield), 216b tR= (8-12) (17 mg, 0.027 mmol, 8.8% 







White solid m.p./127-137 oC; [α]D -16.8 (c 1.25, CH3CN); Rf = 0.83 (40% CH3CN in 
H2O); 
1H NMR (500 MHz, CDCl3) δ ppm: 8.65 (1 H, br.s), 7.32-7.81 (2 H, m), 7.21 (1 
H, d, J = 6.7 Hz), 7.05 (1 H, t, J = 7.2 Hz), 6.86-7.02 (3 H, m), 5.81-5.65 (1 H, m), 5.04-
4.88 (3 H, m), 4.73-4.85 (1 H, m), 4.59-4.72 (1 H, m), 4.4 (1 H, s), 4.00-4.22 (1 H, m), 
3.64-3.99 (1 H, m), 3.37-3.62 (1 H, m), 2.96-3.33 (1 H, m), 2.30-1.64 (8 H, m), 1.62-
1.18 (14 H, m), 0.96-1.15 (1 H, m), 0.75-0.93 (6 H, 2 CH3); 
13C NMR (125 MHz, CDCl3) 
δ ppm: 174.2, 172.3, 171.6, 170.6, 155.6, 138.1, 136.1, 127.8, 124.5, 121.5, 119.2, 
118.5, 114.9, 111.4, 109.1, 80.0, 59.5 (2 C), 55.0, 54.7, 54.1, 47.8, 37.5, 33.2, 32.3, 
28.9, 28.3, 24.8, 24.7, 24.5, 15.3, 10.9; IR (cm-1), 3418, 3297, 3073, 2971, 1694, 
1668, 1633, 1554, 1455, 1239, 1164; m/z (ES+) found: 640.3710, C34H50N5O7 re-
quires MH+ 640.3710.  
Boc-LTP (216a) 
1H NMR (500 MHz, CDCl3) δ ppm: 9.65 (1 H, br.s), 7.75 (1 H, d, J = 6.0 Hz), 7.36 (1 H, 
d, J = 7.8 Hz), 7.03-7.18 (3 H, m), 6.42 (1 H, br.s), 5.68-5.81 (1 H, m), 5.06-5.21 (1 H, 
m), 4.88-5.04 (2 H, m), 4.58-4.71 (2 H, m), 4.24-4.36 (1 H, m), 4.07-4.21 (1 H, m), 
3.72-3.89 (1 H, m), 3.46-3.62 (2 H, m), 3.04-3.28 (2 H, m), 2.86-2.98 (2 H, m), 1.97-
2.16 (6 H, m), 1.74-1.94 (3 H, m), 1.49-1.72 (5 H, m), 1.33-1.47 (12 H, m), 0.94- 1.05 
(1 H, m), 0.74- 0.88 (6 H, m); 13C NMR (125 MHz, CDCl3) δ ppm: 177.2, 171.8, 170.8, 
170.2, 155.6, 138.1, 136.4, 127.6, 125.1, 121.5, 119.1, 118.8, 114.9, 111.5, 109.3, 
79.9, 61.4, 55.0, 54.6, 54.2, 47.8, 44.5, 37.7, 33.3, 32.4, 30.9, 29.5, 28.6, 28.3, 24.7 
(2 C), 24.3, 22.7, 22.5, 15.3, 11.1; m/z (ES+) found: 662.3507, C34H49N5O7Na requires 
MNa+ 662.3530. Extra peaks observed (6 protons and 4 carbon atoms) in aliphatic 









yl)ethyl]carbamoyl)hex-5-en-1-aminium trifluoroacetate (217) 
 




R-Pro-IIe-Trip- N-Boc-α-pentenyl glycine 216c (22 mg, 0.034 mmol, 1 eq.) in DCM (3 
mL) treated with TFA/H2O/TIPS (93/5/2) (130 : 7 : 3) µL, under stirring for 7 hr., to 
give the crude linear peptide 217 (24 mg), it was sufficiently pure to use without 
purification; 13C NMR (100 MHz, CDCl3) δ ppm: 175.1, 172.7, 169.7, 168.1, 136.5, 
135.9, 126.9, 124.8, 121.9, 118.9, 118.2, 115.8, 112.7, 108.4, 59.9, 54.8, 53.9, 47.9, 
37.9, 32.7, 31.9, 30.4, 28.8, 27.9, 24.8, 23.7, 23.1, 15.1, 10.8; m/z (ES+) found: 
540.3162, C29H42N5O5

























To HATU (28 mg, 0.072 mmol, 2 eq.) and DIPEA (16 µL, 0.093 mmol, 2.5 eq.) in dry 
DCM (500 mL) under nitrogen gas, R-Pro-IIe-Trip-N-α-pentenyl glycine (24 mg, 0.036 
mmol, 1 eq.), was added dropwise in period of (1 hr.) at (0 oC) then outside the 
cooling bath stirring continued for (3 hr). Later the solvent removed under reduced 
pressure then the crude was purified by preparative HPLC (XBridge Prep OBD C18 
5µm 19 mmid x 250 mm), using gradient from 95 : 5 to 5 : 95 water/acetonitrile, at 
a flow rate of 17 mL. min-1 and UV detection at 254 nm. The HPLC analysis showed 
two main peaks tR = (17-18) and (25-25.5) that were identified by electrospray mass 
spectrometry as the cyclic tetrapeptide 210 tR = (17-18) (3 mg, 0.006 mmol, 16% 




















1H NMR (500 MHz, CDCl3) δ ppm: 8.03 (1 H, br.s, NH), 7.61 (1 H, d, J = 7.9 Hz, aro-
matic proton), 7.34-7.39 (2 H, m, aromatic proton & NH), 7.19 (1 H, dt, J = 0.7 and 
7.5 Hz, aromatic proton), 7.09-7.17 (2 H, m, aromatic proton & NH), 7.05 (1 H, d, J = 
2.1 Hz, aromatic proton), 6.36 ( 1 H, d, J = 5.8 Hz, NH), 5.76 (1 H, ddt, J = 16.8, 10.2 
and 6.6 Hz, sp2CH), 4.96-5.04 (2 H, m, sp2CH), 4.76 (1 H, dd, J = 7.8  and 1.6 Hz, α-
CH), 4.55 (1 H, t, J = 10.7 Hz, α-CH), 4.13-4.20 (1 H, m, J = 8.4 Hz, α-CH), 3.95-4.03 (1 
H, m, α-CH), 3.82-3.94 (2 H, m, each H belong to two different CH2), 3.58 (1 H, dd, J 
= 14.7 and 6.9 Hz, CH2), 3.51 (1 H, q, J = 8.4 Hz, CH2), 2.34-2.42 (1 H, m, CH2), 2.21-
2.33 ( 1 H, m, CH2), 1.98-2.11 (3 H, m, CH2 & α-CH),  1.88-1.98 (1 H, m), 1.49-1.88 (4 
H, m, 2CH2), 1.24-1.39 (2 H, m), 1.09-1.22 (1 H, m), 0.91 ( 3 H, t, J = 7.6 Hz), 0.88 (3 
H, d, J = 6.7 Hz ); 13C NMR (125 MHz, CDCl3) δ ppm: 175.0, 174.7, 173.5, 171.6, 
138.1, 136.1, 132.4, 127.0, 122.9, 122.2, 119.6, 118.6, 115.0, 111.2, 62.1, 57.8 (2 C), 
54.0, 47.0, 33.8, 33.3, 31.2, 28.6, 25.3, 24.9, 24.8, 24.7, 15.7, 10.7; IR (cm-1), 3444, 
3359, 3045, 2934, 1731, 1650, 1620, 1103; m/z (ES+) found: 522.3067, C29H40N5O4 


















1H NMR (500 MHz, CDCl3) δ ppm: 8.29 (2 H, s), 7.64-8.07 (4 H, br.m), 7.18-7.37 (6 H, 
m), 7.13 (2 H, t, J = 7.5 Hz), 6.91-7.03 (2 H, m), 6.65 (2 H, br.s), 5.76 (2 H, ddt, J = 
16.7, 10.1 and 6.7 Hz), 4.55-5.14 (8 H, m), 4.13-4.51 (4 H, m), 2.69-3.72 (8 H, m), 
2.25-2-40 (2 H, m), 1.19-2.18 (22 H, m), 0.98-1.13 (2 H, m), 0.75-0.97 (12 H, m); 13C 
NMR (125 MHz, CDCl3) δ ppm: 172.5, 172.4, 171.8, 171.5, 137.8, 135.8, 127.2, 
121.9, 121.6, 119.3, 118.6, 115.3, 110.9, 110.8, 59.2 (2 C), 56.2, 53.7, 46.8, 35.8, 
33.2, 31.4, 26.6, 26.5, 25.3, 24.6, 24.4, 15.6, 11.2; m/z (ES+) found: 1043.6123, 

















General procedure D using 210 (5 mg, 0.01 mmol, 1 eq.), vinyl methyl ketone (25 µl, 
0.3 mmol, 30 eq.) and Grubbs 2nd generation catalyst (19 mg, 0.022 mmol, 2.2 eq.) 
in dry degases DCM (3 mL) then after overnight reflux the solvent removed under 
reduced pressure. The crude reaction mixture submitted to hydrogenation by add-
ing 10% pd/C (10 mg, 10 eq.) in EtOAc (4 mL) (24 hr.), under balloon of hydrogen 
gas. The crude product was purified by preparative HPLC (XBridge Prep OBD C18 
5µm 19 mmid x 250 mm), using 70 : 30 water/acetonitrile, at a flow rate of 17 mL. 
min-1 and UV detection at 254 nm. The HPLC analysis showed a main peak at tR = 
(17.5-20) that was identified as apicidin 1 analogue, 221 (3 mg, 0.005 mmol, 50% 
yield over two steps). [α]D -86.7 (c 0.15, CH3CN); Rf  = 0.53 in (2 acetone: 1 hexane) 
mL; 1H NMR (500 MHz, CDCl3) δ ppm: 8.49 (1 H, s, NH), 7.6 (1 H, d, J = 7.5 Hz, aro-
matic proton), 7.35-7.42 (2 H, m, aromatic proton & NH), 7.19 (1 H, t, J = 7.5 Hz, ar-
omatic proton), 7.08-7.16 (2 H, m, aromatic proton & NH), 7.07 (1 H, d, J = 2.1 Hz, 
aromatic proton), 6.26 ( 1 H, d, J = 5.6 Hz, NH), 4.76 ( 1 H, dd, J = 7.7 and 1.5 Hz, α-
CH), 4.6 (1 H, t, J = 10.5 Hz, α-CH), 4.08-4.17 (1 H, m, α-CH), 3.96-4.03 (1 H, m, α-
CH), 3.86-3.95 (2 H, m, for two different CH2 aliphatic), 3.47-3.57 (2 H, m, for two 
different CH2 aliphatic), 2.38-2.47 (2 H, m, aliphatic proton), 2.22-2.38 (2 H, m, ali-
phatic proton), 2.16 (3 H, s, aliphatic proton), 2.01-2.10 (1 H, m, α-CH), 1.89-2.00 ( 3 
H, m, two different aliphatic CH2), 1.77-1.88 (3 H, m, two different aliphatic CH2), 
1.47-1.73 (3 H, m, two different aliphatic CH2), 1.09-1.41 (3 H, m, two different ali-
phatic CH2), 0.93 (3 H, t, J = 7.27 Hz, CH3), 0.88 (3 H, d, J = 6.8 Hz, CH3 ); 
13C NMR 
(125 MHz, CDCl3) δ ppm: 209.7, 174.9, 174.8, 173.5, 171.6, 136.2, 126.9, 123.3, 
122.1, 119.5, 118.5, 111.4, 110.8, 61.9, 57.9, 57.8, 54.0, 46.9, 43.4, 33.9, 29.9, 28.9, 
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28.6, 25.4, 25.3, 24.9 (2 C), 24.8,  23.6, 15.7, 10.7; IR (cm-1), 3339, 3279, 3056, 2959, 
1700, 1664, 1617, 1524, 1444, 1241; m/z (ES+) found: 566.3345, C31H44N5O5 re-









General procedure D using 210 (14 mg, 0.027 mmol, 1 eq.), vinyl propyl ketone (95 
µl, 0.81 mmol, 30 eq.) and Grubbs 2nd generation catalyst (57 mg, 0.067 mmol, 2.5 
eq.) in dry degases DCM (3 mL), then after overnight reflux the solvent removed un-
der reduced pressure. The crude reaction mixture submitted to hydrogenation by 
adding 10% pd/C (28   mg, 10 eq.) in EtOAc (4 mL) (24 hr.), under balloon of hydro-
gen gas. The crude product was purified by preparative HPLC (XBridge Prep OBD 
C18 5µm 19 mmid x 250 mm), using gradient from 95 : 5 to 5 : 95 water/acetonitrile 
in 40 minutes, at a flow rate of 17 mL. min-1 and UV detection at 254 nm. The HPLC 
analysis showed a main peak tR = (22.5-23.5) that was identified as the apicidin 1 
analogue, 222 (7 mg, 0.012 mmol, 44% yield over two steps). [α]D -35.0 (c 0.2, 
CHCl3); Rf = 0.55 in (2 Acetone: 1 hexane); 
1H NMR (500 MHz, CDCl3) δ ppm: 8.53 (1 
H, s, NH), 7.6 (1 H, d, J = 7.5 Hz, aromatic proton), 7.34-7.42 (2 H, m, aromatic pro-
ton & NH), 7.19 (1 H, t, J = 7.4 Hz, aromatic proton), 7.08-7.15 (2 H, m, aromatic 
proton & NH), 7.07 (1 H, d, J = 1.7 Hz, aromatic proton), 6.19 ( 1 H, d, J = 7.7 Hz, 
NH), 4.76 ( 1 H, br.d, J = 6.9 Hz, α-CH), 4.6 (1 H, t, J = 10.5 Hz, α-CH), 4.08-4.16 (1 H, 
m, α-CH), 3.96-4.03 (1 H, m, α-H), 3.85-3.96 (2 H, m, for two different CH2 aliphatic), 
3.46-3.57 (2 H, m, for two different CH2 aliphatic), 2.15-2.46 (6 H, m, 3 CH2 aliphatic 
proton), 2.01-2.12 (1 H, m, α-CH), 1.89-1.98 (1 H, m, aliphatic CH2), 1.77-1.88 (2 H, 
m, 2 different aliphatic CH2), 1.47-1.72 ( 6 H, m, 4 different aliphatic CH2), 1.11-1.36 
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(5 H, m, 3 different aliphatic CH2), 0.94 (3 H, t, J = 7.4 Hz, CH3), 0.93 (3 H, t, J = 7.3 
Hz, CH3), 0.86-0.91 (3 H, m, CH3 ); 
13C NMR (125 MHz, CDCl3) δ ppm: 211.9, 174.9, 
174.8, 173.5, 171.6, 136.3, 126.9, 123.4, 122.1, 119.5, 118.5, 111.4, 110.7, 61.9, 
57.9, 57.8, 54.1, 47.0, 44.8, 42.4, 33.9, 28.9, 28.7, 25.5, 25.3, 24.9 (2 C), 24.8, 23.7, 
17.3, 15.7, 13.8, 10.7; IR (cm-1), 3336, 3309, 3274, 3013, 2966, 1662, 1618, 1523, 
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Table 1.  Crystal data and structure refinement for compound 159b. 
Empirical formula  C15H25NO5 
Formula weight  299.36 
Temperature  97(2) K 
Wavelength  0.71073 Å 
Crystal system  Tetragonal 
Space group  P4(3)2(1)2 
Unit cell dimensions a = 8.8171(6) Å = 90°. 
 b = 8.8171(6) Å = 90°. 
 c = 42.310(3) Å  = 90°. 
Volume 3289.3(4) Å3 
Z 8 
Density (calculated) 1.209 Mg/m3 
Absorption coefficient 0.090 mm-1 
F(000) 1296 
Crystal size 0.32 x 0.10 x 0.10 mm3 
Theta range for data collection 1.93 to 27.73°. 
Index ranges -11<=h<=11, -11<=k<=11, -55<=l<=55 
Reflections collected 32165 
Independent reflections 32165 [R(int) = 0.0000] 
Completeness to theta = 25.00° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9911 and 0.9718 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 32165 / 119 / 216 
Goodness-of-fit on F2 1.131 
Final R indices [I>2sigma(I)] R1 = 0.0555, wR2 = 0.1267 
R indices (all data) R1 = 0.0615, wR2 = 0.1300 
Absolute structure parameter ? 






































Table 6.  Crystal data and structure refinement for compound 194 
Empirical formula  C11H16F3NO5 
Formula weight  299.25 
Temperature  97(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P 21 
Unit cell dimensions a = 8.9295(10) Å = 90°. 
 b = 14.3156(15) Å = 93.139(4)°. 
 c = 21.898(2) Å  = 90°. 
Volume 2795.1(5) Å3 
Z 8 
Density (calculated) 1.422 Mg/m3 
Absorption coefficient 0.135 mm-1 
F(000) 1248 
Crystal size 0.180 x 0.120 x 0.030 mm3 
Theta range for data collection 0.931 to 24.998°. 
Index ranges -8<=h<=10, -17<=k<=17, -26<=l<=25 
Reflections collected 31198 
Independent reflections 9761 [R(int) = 0.1042] 
Completeness to theta = 25.000° 99.8 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.99 and 0.92 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 9761 / 181 / 729 
Goodness-of-fit on F2 1.080 
Final R indices [I>2sigma(I)] R1 = 0.0924, wR2 = 0.2193 
R indices (all data) R1 = 0.1451, wR2 = 0.2483 
Absolute structure parameter ? 
Extinction coefficient n/a 
Largest diff. peak and hole 0.452 and -0.416 e.Å-3 
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Table 1.  Crystal data and structure refinement for 195. 
Empirical formula  C12 H18 F3 N O5 
Formula weight  313.27 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 6.9029(3) Å = 90°. 
 b = 9.9051(5) Å = 90°. 
 c = 21.6344(11) Å  = 90°. 
Volume 1479.23(12) Å3 
Z 4 
Density (calculated) 1.407 Mg/m3 
Absorption coefficient 0.131 mm-1 
F(000) 656 
Crystal size 0.30 x 0.20 x 0.05 mm3 
Theta range for data collection 2.26 to 27.41°. 
Index ranges -8<=h<=8, -12<=k<=12, -27<=l<=27 
Reflections collected 23146 
Independent reflections 3338 [R(int) = 0.0778] 
Completeness to theta = 27.41° 99.6 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9935 and 0.9617 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3338 / 18 / 190 
Goodness-of-fit on F2 1.520 
Final R indices [I>2sigma(I)] R1 = 0.0863, wR2 = 0.2209 
R indices (all data) R1 = 0.1254, wR2 = 0.2401 
Absolute structure parameter 0(2) 
Largest diff. peak and hole 0.722 and -0.588 e.Å-3 
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Table 1.  Crystal data and structure refinement for compound 196. 
Empirical formula  C13H20F3NO5 
Formula weight  327.30 
Temperature  97(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P 21 21 21 
Unit cell dimensions a = 9.7482(14) Å = 90°. 
 b = 22.448(3) Å = 90°. 
 c = 7.0961(12) Å  = 90°. 
Volume 1552.8(4) Å3 
Z 4 
Density (calculated) 1.400 Mg/m3 
Absorption coefficient 0.128 mm-1 
F(000) 688 
Crystal size 0.320 x 0.290 x 0.100 mm3 
Theta range for data collection 1.814 to 26.371°. 
Index ranges -12<=h<=12, -28<=k<=27, -8<=l<=8 
Reflections collected 23033 
Independent reflections 3153 [R(int) = 0.1232] 
Completeness to theta = 25.000° 99.8 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.98 and 0.87 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3153 / 49 / 201 
Goodness-of-fit on F2 1.045 
Final R indices [I>2sigma(I)] R1 = 0.0882, wR2 = 0.2271 
R indices (all data) R1 = 0.1214, wR2 = 0.2506 
Absolute structure parameter ? 
Extinction coefficient n/a 
Largest diff. peak and hole 0.489 and -0.434 e.Å-3 
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Table 1.  Crystal data and structure refinement for compound 197. 
Empirical formula  C14H21NO6 
Formula weight  299.32 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 5.8377(13) Å = 90°. 
 b = 15.109(3) Å = 90°. 
 c = 16.996(4) Å  = 90°. 
Volume 1499.1(6) Å3 
Z 4 
Density (calculated) 1.326 Mg/m3 
Absorption coefficient 0.104 mm-1 
F(000) 640 
Crystal size 0.120 x 0.040 x 0.020 mm3 
Theta range for data collection 1.803 to 27.405°. 
Index ranges -7<=h<=7, -19<=k<=19, -19<=l<=21 
Reflections collected 20198 
Independent reflections 3307 [R(int) = 0.1170] 
Completeness to theta = 25.242° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9979 and 0.9877 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3307 / 0 / 196 
Goodness-of-fit on F2 1.033 
Final R indices [I>2sigma(I)] R1 = 0.0585, wR2 = 0.1179 
R indices (all data) R1 = 0.1245, wR2 = 0.1448 
Absolute structure parameter ? 
Extinction coefficient n/a 
Largest diff. peak and hole 0.243 and -0.331 e.Å-3 
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Table 1.  Crystal data and structure refinement for compound 199. 
Empirical formula  C19H24F3NO5 
Formula weight  403.39 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 8.2038(3) Å = 90°. 
 b = 10.8504(4) Å = 90°. 
 c = 22.9281(9) Å  = 90°. 
Volume 2040.93(13) Å3 
Z 4 
Density (calculated) 1.313 Mg/m3 
Absorption coefficient 0.962 mm-1 
F(000) 848 
Crystal size 0.320 x 0.320 x 0.290 mm3 
Theta range for data collection 3.856 to 66.554°. 
Index ranges -9<=h<=9, -12<=k<=12, -26<=l<=25 
Reflections collected 9563 
Independent reflections 3511 [R(int) = 0.0213] 
Completeness to theta = 67.679° 95.8 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3511 / 19 / 264 
Goodness-of-fit on F2 0.912 
Final R indices [I>2sigma(I)] R1 = 0.0354, wR2 = 0.0930 
R indices (all data) R1 = 0.0365, wR2 = 0.0958 
Absolute structure parameter 0.03(3) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.200 and -0.411 e.Å-3 
 
 
